ATE167523T1 - Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden - Google Patents

Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden

Info

Publication number: ATE167523T1
Authority: AT; Austria
Prior art keywords: nucleic acid; acid hybridization; hybridization assay; immersible; oligonucleotides
Prior art date: 1990-05-11

Application number

AT90309671T

Other languages

English (en)

Inventor

Ness Jeffrey Van

John C Tabone

Charles E Petrie

Nicolaas M J Vermeulen

Original Assignee

Microprobe Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-11

Filing date

1990-09-04

Publication date

1998-07-15

1990-09-04 Application filed by Microprobe Corp filed Critical Microprobe Corp

1998-07-15 Application granted granted Critical

1998-07-15 Publication of ATE167523T1 publication Critical patent/ATE167523T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
238000003556 assay Methods 0.000 title abstract 2
238000007899 nucleic acid hybridization Methods 0.000 title abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
238000000034 method Methods 0.000 title 1
239000011324 bead Substances 0.000 abstract 5
229920000642 polymer Polymers 0.000 abstract 4
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
239000004677 Nylon Substances 0.000 abstract 1
150000007523 nucleic acids Chemical group 0.000 abstract 1
229920001778 nylon Polymers 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Zoology (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Saccharide Compounds (AREA)

AT90309671T 1990-05-11 1990-09-04 Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden ATE167523T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US52244290A	1990-05-11	1990-05-11

Publications (1)

Publication Number	Publication Date
ATE167523T1 true ATE167523T1 (de)	1998-07-15

Family

ID=24080872

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT90309671T ATE167523T1 (de)	1990-05-11	1990-09-04	Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden

Country Status (7)

Country	Link
US (1)	US5514785A (de)
EP (2)	EP0455905B1 (de)
JP (1)	JPH0420300A (de)
AT (1)	ATE167523T1 (de)
DE (1)	DE69032425T2 (de)
DK (1)	DK0455905T3 (de)
ES (1)	ES2116977T3 (de)

Families Citing this family (1036)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6040138A (en)	1995-09-15	2000-03-21	Affymetrix, Inc.	Expression monitoring by hybridization to high density oligonucleotide arrays
DE69132905T2 (de) *	1990-12-06	2002-08-01	Affymetrix, Inc. (N.D.Ges.D.Staates Delaware)	Detektion von Nukleinsäuresequenzen
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
US5747244A (en) *	1991-12-23	1998-05-05	Chiron Corporation	Nucleic acid probes immobilized on polystyrene surfaces
CA2126748A1 (en) *	1991-12-24	1993-06-25	Tepnel Medical Limited	Manipulating nucleic acid sequences
US5795714A (en)	1992-11-06	1998-08-18	Trustees Of Boston University	Method for replicating an array of nucleic acid probes
US6436635B1 (en)	1992-11-06	2002-08-20	Boston University	Solid phase sequencing of double-stranded nucleic acids
US6207651B1 (en) *	1996-08-02	2001-03-27	Metabolite Laboratories	Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
AU675251B2 (en) *	1993-01-04	1997-01-30	Becton Dickinson & Company	Flow-through hybridization assay for oligonucleotide sequences
US6194144B1 (en)	1993-01-07	2001-02-27	Sequenom, Inc.	DNA sequencing by mass spectrometry
US5679510A (en) *	1993-04-27	1997-10-21	Hybridon, Inc.	Quantitative detection of specific nucleic acid sequences using lambdoid bacteriophages linked by oligonucleotides to solid support
CA2170869C (en)	1993-09-03	1999-09-14	Phillip Dan Cook	Amine-derivatized nucleosides and oligonucleosides
DE4409436A1 (de) *	1994-03-19	1995-09-21	Boehringer Mannheim Gmbh	Verfahren zur Bearbeitung von Nukleinsäuren
AU707391B2 (en) *	1994-05-28	1999-07-08	Tepnel Medical Limited	Producing copies of nucleic acids
US7378236B1 (en)	1994-06-17	2008-05-27	The Board Of Trustees Of The Leland Stanford Junior University	Method for analyzing gene expression patterns
US7323298B1 (en) *	1994-06-17	2008-01-29	The Board Of Trustees Of The Leland Stanford Junior University	Microarray for determining the relative abundances of polynuceotide sequences
US5807522A (en) *	1994-06-17	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods for fabricating microarrays of biological samples
US5578446A (en) *	1994-07-08	1996-11-26	Becton Dickinson And Company	Analytical dipstick for improved mixing and reduced reagent volume
US8236493B2 (en) *	1994-10-21	2012-08-07	Affymetrix, Inc.	Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US6428955B1 (en)	1995-03-17	2002-08-06	Sequenom, Inc.	DNA diagnostics based on mass spectrometry
US7803529B1 (en)	1995-04-11	2010-09-28	Sequenom, Inc.	Solid phase sequencing of biopolymers
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
JP3517031B2 (ja) *	1995-06-09	2004-04-05	日清紡績株式会社	生物学的活性物質の分析法
JP2001508281A (ja) *	1995-11-14	2001-06-26	ベイラーカレッジオブメディシン	活性表面化学特性に基づく統合核酸ハイブリダイゼーション装置
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
EP0880598A4 (de)	1996-01-23	2005-02-23	Affymetrix Inc	Verfahren zur analyse von nukleinsäure
US6251691B1 (en)	1996-04-25	2001-06-26	Bioarray Solutions, Llc	Light-controlled electrokinetic assembly of particles near surfaces
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040266706A1 (en) *	2002-11-05	2004-12-30	Muthiah Manoharan	Cross-linked oligomeric compounds and their use in gene modulation
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US20080119427A1 (en) *	1996-06-06	2008-05-22	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
WO1998004740A1 (en) *	1996-07-29	1998-02-05	Nanosphere Llc	Nanoparticles having oligonucleotides attached thereto and uses therefor
US6140053A (en)	1996-11-06	2000-10-31	Sequenom, Inc.	DNA sequencing by mass spectrometry via exonuclease degradation
DE69706187T2 (de) *	1996-11-06	2002-04-11	Sequenom, Inc.	Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern
JP2008298785A (ja) *	1996-11-06	2008-12-11	Sequenom Inc	固体支持体に核酸を固定化するための組成物および方法
CA2702219C (en)	1996-11-06	2013-01-08	Sequenom, Inc.	High density immobilization of nucleic acids
CA2270132A1 (en)	1996-11-06	1998-05-14	Sequenom, Inc.	Dna diagnostics based on mass spectrometry
US5900481A (en) *	1996-11-06	1999-05-04	Sequenom, Inc.	Bead linkers for immobilizing nucleic acids to solid supports
US6133436A (en) *	1996-11-06	2000-10-17	Sequenom, Inc.	Beads bound to a solid support and to nucleic acids
AU2002300406B9 (en) *	1996-11-06	2005-11-03	Sequenom, Inc.	Compositions and Methods for Immobilizing Nucleic Acids to Solid Supports
AU745126B2 (en) *	1997-04-16	2002-03-14	Applied Biosystems, Llc	Nucleic acid archiving
WO1999001579A1 (en)	1997-07-01	1999-01-14	Isis Pharmaceuticals, Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
NZ501776A (en)	1997-07-22	2001-10-26	Qiagen Genomics Inc	Spring probe and methods for arraying oligonucleotide and thickening agent to a solid support
US6268131B1 (en)	1997-12-15	2001-07-31	Sequenom, Inc.	Mass spectrometric methods for sequencing nucleic acids
CA2321100A1 (en) *	1998-02-19	1999-08-26	Edvotek	Articles of manufacture and methods for staining biomolecules
US6013789A (en) *	1998-02-20	2000-01-11	Beckman Coulter, Inc.	Covalent attachment of biomolecules to derivatized polypropylene supports
JP2002504678A (ja) *	1998-02-21	2002-02-12	ビーエーエスエフアクチェンゲゼルシャフト	表面分析のための蛍光染料の使用
US20040186071A1 (en) *	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US7321828B2 (en) *	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
US6048695A (en) *	1998-05-04	2000-04-11	Baylor College Of Medicine	Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6979728B2 (en) *	1998-05-04	2005-12-27	Baylor College Of Medicine	Articles of manufacture and methods for array based analysis of biological molecules
US6723564B2 (en)	1998-05-07	2004-04-20	Sequenom, Inc.	IR MALDI mass spectrometry of nucleic acids using liquid matrices
CA2329130A1 (en) *	1998-05-21	1999-11-25	Isis Pharmaceuticals Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
AU753270B2 (en) *	1998-05-21	2002-10-10	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
US6335439B1 (en)	1998-06-11	2002-01-01	Isis Pharmaceuticals, Inc.	Method of preparing phosphoramidites
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6667176B1 (en)	2000-01-11	2003-12-23	Geron Corporation	cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
BE1012275A3 (fr) *	1998-11-12	2000-08-01	Univ Bruxelles	Fixation covalente d'oligonucleotides a la surface du nylon.
AU764964B2 (en) *	1998-11-23	2003-09-04	Usamriid	Purification method and apparatus
US6638760B1 (en) *	1998-11-25	2003-10-28	Pe Corporation (Ny)	Method and apparatus for flow-through hybridization
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
DE19903576C2 (de)	1999-01-29	2001-02-22	Bodenseewerk Perkin Elmer Co	Quantitative Bestimmung von Analyten in einem heterogenen System
EP1722236A1 (de) *	1999-02-16	2006-11-15	Applera Corporation	System zur Kügelchenausgabe
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6268141B1 (en) *	1999-05-12	2001-07-31	Beckman Coulter, Inc.	Immobilization of unmodified biopolymers to acyl fluoride activated substrates
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6339147B1 (en)	1999-07-29	2002-01-15	Epoch Biosciences, Inc.	Attachment of oligonucleotides to solid supports through Schiff base type linkages for capture and detection of nucleic acids
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6617442B1 (en) *	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
US7332275B2 (en) *	1999-10-13	2008-02-19	Sequenom, Inc.	Methods for detecting methylated nucleotides
WO2001032935A2 (en) *	1999-11-02	2001-05-10	Celine Hu	Molecular microarrays and methods for production and use thereof
US7109024B2 (en) *	1999-11-15	2006-09-19	Dr. Chip Biotechnology Inc.	Biomolecule-bound substrates
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
WO2001058561A1 (en) *	2000-02-09	2001-08-16	Resq Lab B.V.	Packing materials for separation of biomolecules
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
US6413722B1 (en)	2000-03-22	2002-07-02	Incyte Genomics, Inc.	Polymer coated surfaces for microarray applications
US6911535B2 (en) *	2000-03-22	2005-06-28	Solvlink Biosciences	Biomolecule/polymer conjugates
WO2001079284A2 (en) *	2000-04-13	2001-10-25	Wight Thomas N	Therapeutic compounds and methods for formulating v3, a versican isoform
US6458589B1 (en)	2000-04-27	2002-10-01	Geron Corporation	Hepatocyte lineage cells derived from pluripotent stem cells
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
WO2001094630A2 (en) *	2000-06-07	2001-12-13	Baylor College Of Medicine	Compositions and methods for array-based nucleic acid hybridization
US20060166227A1 (en) *	2000-06-20	2006-07-27	Stephen Kingsmore	Protein expression profiling
US9709559B2 (en)	2000-06-21	2017-07-18	Bioarray Solutions, Ltd.	Multianalyte molecular analysis using application-specific random particle arrays
AU7299301A (en)	2000-06-21	2002-01-02	Bioarray Solutions Ltd	Multianalyte molecular analysis using application-specific random particle arrays
US6323009B1 (en) *	2000-06-28	2001-11-27	Molecular Staging, Inc.	Multiply-primed amplification of nucleic acid sequences
US6958214B2 (en)	2000-07-10	2005-10-25	Sequenom, Inc.	Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
JP5305553B2 (ja)	2000-10-12	2013-10-02	ユニバーシティーオブロチェスター	癌細胞の増殖を阻害する組成物
US20030045005A1 (en) *	2000-10-17	2003-03-06	Michael Seul	Light-controlled electrokinetic assembly of particles near surfaces
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2002061146A1 (en) *	2001-02-01	2002-08-08	The Trustees Of Columbia University In The City Of New York	Use of electrical fields to control interactions between proteins and nucleic acid constructions immobilized on solid supports
AU2002257067A1 (en)	2001-03-14	2002-09-24	Myriad Genetics, Inc	Tsg101-gag interaction and use thereof
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP1409549A4 (de)	2001-06-20	2007-10-24	Genentech Inc	Zusammensetzungen und verfahren für die diagnose und behandlung von tumoren
US7803915B2 (en) *	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
CA2451643C (en)	2001-06-21	2012-11-13	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US7262063B2 (en)	2001-06-21	2007-08-28	Bio Array Solutions, Ltd.	Directed assembly of functional heterostructures
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
EP1759210B1 (de)	2001-07-13	2008-12-31	Nanosphere, Inc.	Verfahren zur herstellung von substraten mit immobilisierten molekülen und substraten
US7687437B2 (en)	2001-07-13	2010-03-30	Nanosphere, Inc.	Method for immobilizing molecules onto surfaces
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
NZ573739A (en)	2001-09-18	2010-07-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201
US7195913B2 (en)	2001-10-05	2007-03-27	Surmodics, Inc.	Randomly ordered arrays and methods of making and using
US8158106B2 (en)	2001-10-05	2012-04-17	Surmodics, Inc.	Particle immobilized coatings and uses thereof
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ577565A (en)	2001-10-09	2010-10-29	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expressions
CA2463725A1 (en) *	2001-10-12	2003-11-06	Spectral Genomics, Inc.	Compilations of nucleic acids and arrays and methods of using them
US7439346B2 (en) *	2001-10-12	2008-10-21	Perkinelmer Las Inc.	Nucleic acids arrays and methods of use therefor
ES2712173T3 (es)	2001-10-15	2019-05-09	Bioarray Solutions Ltd	Análisis multiplexado de loci polimórficos mediante consulta simultánea y detección mediada por enzimas
US20030228319A1 (en)	2002-04-16	2003-12-11	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20030170678A1 (en) *	2001-10-25	2003-09-11	Neurogenetics, Inc.	Genetic markers for Alzheimer's disease and methods using the same
US20030224380A1 (en) *	2001-10-25	2003-12-04	The General Hospital Corporation	Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
AU2002364945A1 (en) *	2001-10-25	2003-07-09	Neurogenetics, Inc.	Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
DE10154291B4 (de) *	2001-11-05	2005-05-19	Hain Lifescience Gmbh	Verfahren zum Nachweis von Nukleinsäuren in Form eines Trockenschnelltestes
WO2003042697A1 (en) *	2001-11-14	2003-05-22	Genospectra, Inc.	Biochemical analysis system with combinatorial chemistry applications
US6927029B2 (en)	2001-12-03	2005-08-09	Agilent Technologies, Inc.	Surface with tethered polymeric species for binding biomolecules
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
US20030119203A1 (en)	2001-12-24	2003-06-26	Kimberly-Clark Worldwide, Inc.	Lateral flow assay devices and methods for conducting assays
US8367013B2 (en) *	2001-12-24	2013-02-05	Kimberly-Clark Worldwide, Inc.	Reading device, method, and system for conducting lateral flow assays
JP3634307B2 (ja) *	2001-12-27	2005-03-30	三菱電機株式会社	チャット管理システム
US20030124542A1 (en) *	2001-12-28	2003-07-03	Spectral Genomics, Inc.	Methods for mapping the chromosomal loci of genes expressed by a cell
EP1575571A4 (de)	2002-01-02	2008-06-25	Genentech Inc	Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
WO2003064679A2 (en) *	2002-01-30	2003-08-07	Id Biomedical Corporation	Methods for detecting vancomycin-resistant microorganisms and compositions therefor
CA2474530A1 (en) *	2002-02-07	2003-08-14	Eastern Virginia Medical School Of The Medical College Of Hampton Roads	Diagnostic microarray and method of use thereof
US7553619B2 (en) *	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
WO2003080649A2 (en) *	2002-03-20	2003-10-02	Regents Of The University Of Minnesota	Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
CA2484676A1 (en) *	2002-05-03	2003-11-13	Sequenom, Inc.	Kinase anchor protein muteins, peptides thereof, and related methods
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
AU2003276131A1 (en) *	2002-06-18	2003-12-31	Epigenesis Pharmaceuticals, Inc.	A dry powder oligonucleotide formulation, preparation and its uses
JP2004097173A (ja) *	2002-07-17	2004-04-02	Toyo Kohan Co Ltd	静電層を有する固体支持体及びその用途
US20040019000A1 (en) *	2002-07-19	2004-01-29	Muthiah Manoharan	Polyalkyleneamine-containing oligomers
US20050287648A1 (en)	2002-08-05	2005-12-29	University Of Rochester	Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
US6878805B2 (en) *	2002-08-16	2005-04-12	Isis Pharmaceuticals, Inc.	Peptide-conjugated oligomeric compounds
US7619819B2 (en)	2002-08-20	2009-11-17	Illumina, Inc.	Method and apparatus for drug product tracking using encoded optical identification elements
US7441703B2 (en)	2002-08-20	2008-10-28	Illumina, Inc.	Optical reader for diffraction grating-based encoded optical identification elements
US7900836B2 (en)	2002-08-20	2011-03-08	Illumina, Inc.	Optical reader system for substrates having an optically readable code
US7872804B2 (en)	2002-08-20	2011-01-18	Illumina, Inc.	Encoded particle having a grating with variations in the refractive index
US7901630B2 (en)	2002-08-20	2011-03-08	Illumina, Inc.	Diffraction grating-based encoded microparticle assay stick
US7508608B2 (en)	2004-11-17	2009-03-24	Illumina, Inc.	Lithographically fabricated holographic optical identification element
WO2004019277A1 (en) *	2002-08-20	2004-03-04	Cyvera Corporation	Diffraction grating-based encoded micro-particles for multiplexed experiments
EP1535241A1 (de) *	2002-08-20	2005-06-01	Cyvera Corporation	Auf einem beugungsgitter basierendes optisches identifikationselement
US7164533B2 (en)	2003-01-22	2007-01-16	Cyvera Corporation	Hybrid random bead/chip based microarray
US7923260B2 (en)	2002-08-20	2011-04-12	Illumina, Inc.	Method of reading encoded particles
US7285424B2 (en) *	2002-08-27	2007-10-23	Kimberly-Clark Worldwide, Inc.	Membrane-based assay devices
US7432105B2 (en)	2002-08-27	2008-10-07	Kimberly-Clark Worldwide, Inc.	Self-calibration system for a magnetic binding assay
US7314763B2 (en) *	2002-08-27	2008-01-01	Kimberly-Clark Worldwide, Inc.	Fluidics-based assay devices
CA2499037A1 (en) *	2002-09-12	2004-03-25	Cyvera Corporation	Method and apparatus for labelling using diffraction grating-based encoded optical identification elements
EP1552475A1 (de) *	2002-09-12	2005-07-13	Cyvera Corporation	Chemische synthese unter verwendung von beugungsgitter-gestützten kodierten optischen elementen
WO2004025560A1 (en) *	2002-09-12	2004-03-25	Cyvera Corporation	Assay stick comprising coded microbeads
EP1575707A1 (de) *	2002-09-12	2005-09-21	Cyvera Corporation	Verfahren und vorrichtung zur ausrichtung von länglichen mikroperlen zu deren untersuchung
US7092160B2 (en)	2002-09-12	2006-08-15	Illumina, Inc.	Method of manufacturing of diffraction grating-based optical identification element
AU2003270726A1 (en) *	2002-09-12	2004-04-30	Cidra Corporation	Diffraction grating-based encoded micro-particles for multiplexed experiments
US20100255603A9 (en)	2002-09-12	2010-10-07	Putnam Martin A	Method and apparatus for aligning microbeads in order to interrogate the same
EA008940B1 (ru)	2002-09-13	2007-10-26	Репликор, Инк.	Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
EP1556325A4 (de) *	2002-09-20	2007-09-19	Integrated Dna Tech Inc	Anthrachinonquencherfarbstoffe, verfahren zu deren herstellung und verwendung
CA2499770A1 (en)	2002-09-20	2004-04-01	Yale University	Riboswitches, methods for their use, and compositions for use with riboswitches.
AU2003278957A1 (en)	2002-09-26	2004-04-23	Amgen, Inc.	Modulation of forkhead box o1a expression
EP1560597A4 (de) *	2002-10-29	2007-06-27	Pharmacia Corp	Differentiell ausgedrückte krebsgene, dabei kodierte polypeptide und verfahren zu ihrer verwendung
CA2504694C (en)	2002-11-05	2013-10-01	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8604183B2 (en)	2002-11-05	2013-12-10	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004044138A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003294281B2 (en)	2002-11-13	2010-05-20	Kastle Therapeutics, Llc	Antisense modulation of apolipoprotein B expression
SI1569695T1 (sl)	2002-11-13	2013-08-30	Genzyme Corporation	Protismiselna modulacija ekspresije apolipoproteina B
WO2004046330A2 (en) *	2002-11-15	2004-06-03	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
WO2004047007A1 (en)	2002-11-15	2004-06-03	Bioarray Solutions, Ltd.	Analysis, secure access to, and transmission of array images
CN100594037C (zh)	2002-11-15	2010-03-17	Musc研究发展基金会	通过补体受体2定向的补体调节剂
AU2003294462C1 (en)	2002-11-21	2011-06-30	University Of Utah Research Foundation	Purinergic modulation of smell
US7781172B2 (en) *	2003-11-21	2010-08-24	Kimberly-Clark Worldwide, Inc.	Method for extending the dynamic detection range of assay devices
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US7247500B2 (en) *	2002-12-19	2007-07-24	Kimberly-Clark Worldwide, Inc.	Reduction of the hook effect in membrane-based assay devices
US20040121339A1 (en) *	2002-12-19	2004-06-24	Jizhong Zhou	Special film-coated substrate for bio-microarray fabrication and use thereof
US20040121334A1 (en) *	2002-12-19	2004-06-24	Kimberly-Clark Worldwide, Inc.	Self-calibrated flow-through assay devices
CA2510587A1 (en)	2002-12-20	2004-07-15	Qiagen Gmbh	Nucleic acid amplification
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
US6977153B2 (en) *	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
US8081792B2 (en)	2003-08-20	2011-12-20	Illumina, Inc.	Fourier scattering methods for encoding microbeads and methods and apparatus for reading the same
EP1597366B1 (de)	2003-02-11	2012-11-21	Antisense Therapeutics Ltd	Modulation der expression des insulinähnlichen wachstumsfaktor i-rezeptors
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20070141570A1 (en) *	2003-03-07	2007-06-21	Sequenom, Inc.	Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US20040197819A1 (en) *	2003-04-03	2004-10-07	Kimberly-Clark Worldwide, Inc.	Assay devices that utilize hollow particles
US7851209B2 (en) *	2003-04-03	2010-12-14	Kimberly-Clark Worldwide, Inc.	Reduction of the hook effect in assay devices
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
EP1660512A4 (de) *	2003-06-02	2009-12-23	Isis Pharmaceuticals Inc	Oligonucleotid-synthese mit alternativen lösungsmitteln
JP4579911B2 (ja)	2003-06-03	2010-11-10	アイシス・ファーマシューティカルズ・インコーポレイテッド	スルビビン発現の調節
ES2905724T3 (es)	2003-06-13	2022-04-11	Alnylam Europe Ag	Acido ribonucleico bicatenario con elevada eficacia en un organismo
US7790691B2 (en) *	2003-06-20	2010-09-07	Isis Pharmaceuticals, Inc.	Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation
WO2005013901A2 (en)	2003-07-31	2005-02-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) *	2003-09-11	2007-05-31	Replicor Inc.	Oligonucleotides targeting prion diseases
WO2005029705A2 (en)	2003-09-18	2005-03-31	Bioarray Solutions, Ltd.	Number coding for identification of subtypes of coded types of solid phase carriers
EP2182063A3 (de)	2003-09-18	2012-07-18	Isis Pharmaceuticals, Inc.	Modulierung von EIF4E-Expression
WO2005027962A1 (en) *	2003-09-18	2005-03-31	Isis Pharmaceuticals, Inc.	4’-thionucleosides and oligomeric compounds
PT1664722E (pt)	2003-09-22	2011-12-28	Bioarray Solutions Ltd	Polielectrólito imobilizado à superfície com grupos funcionais múltiplos capazes de se ligarem covalentemente às biomoléculas
WO2005035548A1 (en)	2003-10-10	2005-04-21	Meditech Research Limited	The moduilation of hyaluronan synthesis and degradation in the treatment of disease
EP1692298A4 (de)	2003-10-28	2008-08-13	Bioarray Solutions Ltd	Optimierung der genexpressionsanalyse unter verwendung immobilisierter fängersonden
WO2005045060A2 (en)	2003-10-29	2005-05-19	Bioarray Solutions, Ltd.	Multiplexed nucleic acid analysis by fragmentation of double-stranded dna
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
US7439341B2 (en) *	2003-11-14	2008-10-21	Integrated Dna Technologies, Inc.	Fluorescence quenching azo dyes, their methods of preparation and use
NZ576411A (en)	2003-11-17	2010-04-30	Genentech Inc	Compositions and methods for the treatment of tumor of hematopoietic origin
US20050112703A1 (en)	2003-11-21	2005-05-26	Kimberly-Clark Worldwide, Inc.	Membrane-based lateral flow assay devices that utilize phosphorescent detection
US7943395B2 (en) *	2003-11-21	2011-05-17	Kimberly-Clark Worldwide, Inc.	Extension of the dynamic detection range of assay devices
US7713748B2 (en) *	2003-11-21	2010-05-11	Kimberly-Clark Worldwide, Inc.	Method of reducing the sensitivity of assay devices
US20050136500A1 (en) *	2003-12-19	2005-06-23	Kimberly-Clark Worldwide; Inc.	Flow-through assay devices
US7943089B2 (en) *	2003-12-19	2011-05-17	Kimberly-Clark Worldwide, Inc.	Laminated assay devices
US20050136550A1 (en) *	2003-12-19	2005-06-23	Kimberly-Clark Worldwide, Inc.	Flow control of electrochemical-based assay devices
WO2005071080A2 (en)	2004-01-20	2005-08-04	Isis Pharmaceuticals, Inc.	Modulation of glucocorticoid receptor expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US7468431B2 (en) *	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US7433123B2 (en)	2004-02-19	2008-10-07	Illumina, Inc.	Optical identification element having non-waveguide photosensitive substrate with diffraction grating therein
US20050191704A1 (en) *	2004-03-01	2005-09-01	Kimberly-Clark Worldwide, Inc.	Assay devices utilizing chemichromic dyes
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005089268A2 (en)	2004-03-15	2005-09-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of rna by rnase h
US20050244869A1 (en) *	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
EP2540734B1 (de)	2004-04-05	2016-03-30	Alnylam Pharmaceuticals, Inc.	Prozess und Reagenzien für Oligonukleotidsynthese und -reinigung
US20050260755A1 (en) *	2004-04-06	2005-11-24	Isis Pharmaceuticals, Inc.	Sequential delivery of oligomeric compounds
US20050260652A1 (en) *	2004-04-15	2005-11-24	The General Hospital Corporation	Compositions and methods that modulate RNA interference
AU2005323437B2 (en)	2004-04-30	2011-10-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a C5-modified pyrimidine
US8039588B2 (en)	2004-05-21	2011-10-18	The Uab Research Foundation	Variable lymphocyte receptors
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
EP1766052A4 (de) *	2004-06-03	2009-12-16	Isis Pharmaceuticals Inc	Chimärische oligomere zusammensetzungen mit gap
US7906276B2 (en)	2004-06-30	2011-03-15	Kimberly-Clark Worldwide, Inc.	Enzymatic detection techniques
US7521226B2 (en)	2004-06-30	2009-04-21	Kimberly-Clark Worldwide, Inc.	One-step enzymatic and amine detection technique
US7094528B2 (en) *	2004-06-30	2006-08-22	Kimberly-Clark Worldwide, Inc.	Magnetic enzyme detection techniques
US7848889B2 (en)	2004-08-02	2010-12-07	Bioarray Solutions, Ltd.	Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
WO2006023880A2 (en) *	2004-08-23	2006-03-02	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006032143A1 (en)	2004-09-23	2006-03-30	Arc Pharmaceuticals, Inc.	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
JP2008516991A (ja)	2004-10-20	2008-05-22	アンチセンスセラピューティクスリミテッド	インテグリンα４発現のアンチセンス調節
US7604173B2 (en)	2004-11-16	2009-10-20	Illumina, Inc.	Holographically encoded elements for microarray and other tagging labeling applications, and method and apparatus for making and reading the same
US7602952B2 (en)	2004-11-16	2009-10-13	Illumina, Inc.	Scanner having spatial light modulator
WO2006063031A2 (en)	2004-12-06	2006-06-15	Haplomics	Allelic variants of human factor viii
MX2007010922A (es)	2005-03-10	2007-10-12	Genentech Inc	Metodos y composiciones para modular la integridad vascular.
US7476733B2 (en) *	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
EP1863908B1 (de)	2005-04-01	2010-11-17	Qiagen GmbH	Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
WO2006125124A2 (en) *	2005-05-18	2006-11-23	Nanosphere, Inc.	Substrate functionalization method for high sensitivity applications
WO2006127507A2 (en)	2005-05-20	2006-11-30	Integrated Dna Technologies, Inc.	Compounds and methods for labeling oligonucleotides
WO2007008300A2 (en)	2005-05-31	2007-01-18	ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE	Triblock copolymers for cytoplasmic delivery of gene-based drugs
US8486629B2 (en)	2005-06-01	2013-07-16	Bioarray Solutions, Ltd.	Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation
US20090209621A1 (en)	2005-06-03	2009-08-20	The Johns Hopkins University	Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007032837A2 (en)	2005-08-11	2007-03-22	The J. Craig Venter Institute	Method for in vitro recombination
KR20080036646A (ko)	2005-08-17	2008-04-28	메덱시스 에스.에이.	Ｃｋ１９ 발현 측정을 위한 조성물 및 방법
ATE494372T1 (de)	2005-08-29	2011-01-15	Regulus Therapeutics Inc	Verfahren für mir-122a-modulation
WO2007027894A2 (en)	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Antisense compounds having enhanced anti-microrna activity
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
EP2395076A1 (de)	2005-10-14	2011-12-14	MUSC Foundation For Research Development	Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP2325315B1 (de)	2005-10-28	2014-05-07	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Expression des Huntingtin-Gens
AU2006311725B2 (en) *	2005-11-04	2011-11-24	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of NAV1.8 gene
CA2626690A1 (en)	2005-11-09	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
CA2630602A1 (en)	2005-11-21	2007-05-31	Isis Pharmaceuticals, Inc.	Modulation of eif4e-bp2 expression
US7623624B2 (en)	2005-11-22	2009-11-24	Illumina, Inc.	Method and apparatus for labeling using optical identification elements characterized by X-ray diffraction
JP2009524411A (ja) *	2005-12-21	2009-07-02	イェールユニバーシティー	リボスイッチの調節に関連した方法および組成物
CN103301475B (zh)	2005-12-28	2016-08-03	斯克里普斯研究所	药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
EP2422819B1 (de)	2006-01-26	2017-03-01	Ionis Pharmaceuticals, Inc.	Zusammensetzung und deren Verwendungen in Bezug auf Huntingtin
DE602007009487D1 (de) *	2006-01-27	2010-11-11	Isis Pharmaceutical Inc	6-modifizierte bicyclische nukleinsäureanaloga
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
EP2388328A1 (de)	2006-01-27	2011-11-23	Isis Pharmaceuticals, Inc.	Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von microRNAs
US20090305262A1 (en) *	2006-03-31	2009-12-10	Canon Kabushiki Kaisha	Probe, probe set, probe-immobilized carrier, and genetic testing method
JP5704741B2 (ja)	2006-03-31	2015-04-22	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｅｇ５遺伝子発現の抑制のための組成物および方法
US7830575B2 (en)	2006-04-10	2010-11-09	Illumina, Inc.	Optical scanner with improved scan time
WO2007130434A2 (en) *	2006-05-02	2007-11-15	Applera Corporation	Variable volume dispenser and method
CN101437943A (zh) *	2006-05-03	2009-05-20	波罗的科技发展有限公司	牢固结合的碱基-修饰的寡核苷酸和人工核酸酶组合的反义药剂
EP2505647A1 (de)	2006-05-05	2012-10-03	Isis Pharmaceuticals, Inc.	Verbindungen und Verfahren zur Modulation der Expression von DGAT2
EP2505646A1 (de) *	2006-05-05	2012-10-03	Isis Pharmaceuticals, Inc.	Verbindungen und Verfahren zur Modulation der Expression von CRP
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
CA2651453C (en) *	2006-05-11	2014-10-14	Isis Pharmaceuticals, Inc.	5'-modified bicyclic nucleic acid analogs
EP2392583A1 (de)	2006-05-19	2011-12-07	Alnylam Europe AG.	RNAi-Modulation von AHA und therapeutische Verwendungen davon
US7888498B2 (en)	2006-05-22	2011-02-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of IKK-B gene
EP2023938A4 (de) *	2006-05-23	2010-11-10	Isis Pharmaceuticals Inc	Modulation von chrebp-expression
US20090280188A1 (en) *	2006-06-23	2009-11-12	Northwestern University	Asymmetric functionalizated nanoparticles and methods of use
WO2008011473A2 (en)	2006-07-19	2008-01-24	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to hbxip
WO2008017081A1 (en) *	2006-08-04	2008-02-07	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of jnk proteins
US20090047673A1 (en) *	2006-08-22	2009-02-19	Cary Robert B	Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
EP2061799A4 (de) *	2006-09-11	2010-12-22	Univ Yale	Verfahren und zusammensetzungen zur verwendung von lysin-riboswitches
KR101556798B1 (ko)	2006-10-05	2015-10-01	메사츄세츠 인스티튜트 어브 테크놀로지	고성능 분석을 위한 다중기능성 인코딩된 입자
EP2410053B2 (de)	2006-10-18	2020-07-15	Ionis Pharmaceuticals, Inc.	Antisense-verbindungen
WO2008136852A2 (en)	2006-11-01	2008-11-13	University Of Rochester	Methods and compositions related to the structure and function of apobec3g
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
EA200900741A1 (ru) *	2006-11-27	2010-04-30	Айзис Фармасьютикалз, Инк.	Способы лечения гиперхолестеринемии
JP2010512327A (ja)	2006-12-11	2010-04-22	ユニヴァーシティーオブユタリサーチファウンデーション	病的血管形成および脈管透過性の処置用の組成物および方法
US20100129358A1 (en)	2006-12-22	2010-05-27	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
AU2008212820B2 (en) *	2007-02-09	2014-01-30	Northwestern University	Particles for detecting intracellular targets
CA2679586A1 (en) *	2007-02-27	2008-10-23	Northwestern University	Molecule attachment to nanoparticles
KR20100015757A (ko)	2007-03-22	2010-02-12	예일 유니버시티	택일적 스플라이싱을 조절하는 리보스위치와 관련된 방법 및 조성물
JP5350360B2 (ja)	2007-03-29	2013-11-27	アルナイラムファーマシューティカルズ，インコーポレイテッド	エボラ由来の遺伝子の発現を阻害するための組成物および方法
US20110091377A1 (en)	2007-05-11	2011-04-21	The Johns Hopkins University	Biomarkers for melanoma
EP2426219A1 (de)	2007-05-29	2012-03-07	Yale University	Riboswitches sowie Verfahren und Zusammensetzungen zur Verwendung von und mit Riboswitches
CN101688251A (zh) *	2007-05-29	2010-03-31	耶鲁大学	与控制可变剪接和rna加工的核糖开关有关的方法和组合物
DK2170917T3 (da)	2007-05-30	2012-10-08	Isis Pharmaceuticals Inc	N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
EP2826863B1 (de)	2007-05-30	2017-08-23	Northwestern University	Nukleinsäurefunktionalisierte Nanopartikel für therapeutische Anwendungen
US7807372B2 (en) *	2007-06-04	2010-10-05	Northwestern University	Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
WO2008154401A2 (en)	2007-06-08	2008-12-18	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) *	2007-07-05	2012-09-13	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
EP2188298B1 (de)	2007-08-15	2013-09-18	Isis Pharmaceuticals, Inc.	Tetrahydropyrannukleinsäureanaloga
JP2010538005A (ja)	2007-08-28	2010-12-09	ユーエービーリサーチファウンデーション	合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296487A1 (en)	2007-08-28	2009-03-12	The Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009039466A1 (en)	2007-09-20	2009-03-26	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
WO2009039442A1 (en) *	2007-09-21	2009-03-26	California Institute Of Technology	Nfia in glial fate determination, glioma therapy and astrocytoma treatment
CA2700953A1 (en)	2007-10-02	2009-04-09	Amgen Inc.	Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
MX2010004984A (es) *	2007-11-05	2010-07-29	Baltic Technology Dev Ltd	Uso de oligonucleotidos con bases modificadas en hibridacion de acidos nucleicos.
WO2009067243A2 (en) *	2007-11-20	2009-05-28	Isis Pharmaceuticals Inc.	Modulation of cd40 expression
WO2009076400A2 (en)	2007-12-10	2009-06-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor vii gene
EP3100718B1 (de)	2008-01-02	2019-11-27	Arbutus Biopharma Corporation	Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
EP2265627A2 (de) *	2008-02-07	2010-12-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexitolnukleinsäureanaloga
US20090215050A1 (en)	2008-02-22	2009-08-27	Robert Delmar Jenison	Systems and methods for point-of-care amplification and detection of polynucleotides
CN105267233B (zh)	2008-03-05	2019-07-26	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因表达的组合物和方法
US8426378B2 (en) *	2008-03-21	2013-04-23	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucelosides and methods for their use
EP2105145A1 (de) *	2008-03-27	2009-09-30	ETH Zürich	Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
US9290534B2 (en) *	2008-04-04	2016-03-22	Ionis Pharmaceuticals, Inc.	Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
US8846639B2 (en) *	2008-04-04	2014-09-30	Isis Pharmaceutical, Inc.	Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
US8575123B2 (en)	2008-04-11	2013-11-05	Tekmira Pharmaceuticals Corporation	Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
AU2009237577B2 (en)	2008-04-18	2014-06-05	Baxter Healthcare Sa	Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US8324366B2 (en)	2008-04-29	2012-12-04	Alnylam Pharmaceuticals, Inc.	Compositions and methods for delivering RNAI using lipoproteins
US20090274696A1 (en) *	2008-04-29	2009-11-05	Wyeth	Methods for treating inflammation
CA2723536C (en)	2008-05-05	2017-06-13	Los Alamos National Security, Llc	Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control
CA2726052A1 (en)	2008-06-04	2009-12-10	The Board Of Regents Of The University Of Texas System	Modulation of gene expression through endogenous small rna targeting of gene promoters
AU2009276763B2 (en)	2008-07-29	2015-07-16	The Board Of Regents Of The University Of Texas Sytem	Selective inhibition of polyglutamine protein expression
EP2323667A4 (de) *	2008-08-07	2012-07-25	Isis Pharmaceuticals Inc	Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
EP2334319B1 (de)	2008-08-25	2017-12-06	Excaliard Pharmaceuticals, Inc.	Verfahren zur verminderten narbenbildung während der wundheilung anhand von ctgf-ausgerichteten antisense-verbindungen
CN107083386A (zh)	2008-08-25	2017-08-22	埃克斯雷德制药有限公司	阻止结缔组织生长因子的反义核苷酸及其用途
EP2690175B1 (de)	2008-09-02	2016-12-28	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
WO2010039548A2 (en)	2008-09-23	2010-04-08	Alnylam Pharmaceuticals, Inc.	Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010036698A1 (en) *	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Substituted alpha-l-bicyclic nucleosides
WO2010036696A1 (en)	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acid analogs
US8546554B2 (en)	2008-09-25	2013-10-01	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
AU2009303345B2 (en)	2008-10-09	2015-08-20	Arbutus Biopharma Corporation	Improved amino lipids and methods for the delivery of nucleic acids
CA2740785C (en)	2008-10-15	2017-06-20	Isis Pharmaceuticals, Inc.	Modulation of factor 11 expression
EP2937418B1 (de)	2008-10-20	2017-10-18	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Expression des Transthyretin
EP2447274B1 (de)	2008-10-24	2017-10-04	Ionis Pharmaceuticals, Inc.	Oligomerverbindungen und Verfahren
EP2358397B1 (de)	2008-10-24	2020-01-01	Ionis Pharmaceuticals, Inc.	5 - und 2 -bis-substituierte nukleoside und daraus hergestellte oligomere verbindungen
EP3699172A3 (de)	2008-11-10	2020-11-18	Arbutus Biopharma Corporation	Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
AU2009316286B2 (en)	2008-11-24	2016-05-26	Northwestern University	Polyvalent RNA-nanoparticle compositions
JP6099868B2 (ja)	2008-12-04	2017-03-22	クルナ・インコーポレーテッド	サーチュイン１（ｓｉｒｔ１）に対する天然アンチセンス転写物の抑制によるサーチュイン１関連疾患の治療
KR20110091796A (ko)	2008-12-04	2011-08-12	오피케이오 큐알엔에이, 엘엘씨	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CA2745329C (en)	2008-12-04	2022-07-12	Opko Curna, Llc	Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
EP2373382B1 (de)	2008-12-10	2017-02-15	Alnylam Pharmaceuticals, Inc.	Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2010203474B2 (en) *	2009-01-08	2015-11-19	Northwestern University	Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
EP2391343B1 (de)	2009-01-29	2017-03-01	Arbutus Biopharma Corporation	Verbesserte lipidformulierung zur verabreichung von nukleinsaueren
EP2393825A2 (de)	2009-02-06	2011-12-14	Isis Pharmaceuticals, Inc.	Oligomere verbindungen und verfahren
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
JP6066035B2 (ja)	2009-02-12	2017-01-25	クルナ・インコーポレーテッド	グリア細胞由来神経栄養因子（ｇｄｎｆ）関連疾病の、ｇｄｎｆに対する天然アンチセンス転写物の抑制による治療
HUE026280T2 (en)	2009-02-12	2016-06-28	Curna Inc	Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
US8975389B2 (en)	2009-03-02	2015-03-10	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
EP2963116B1 (de)	2009-03-04	2020-11-11	CuRNA, Inc.	Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
CA2754043A1 (en)	2009-03-12	2010-09-16	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
MX2011009751A (es)	2009-03-16	2011-09-29	Opko Curna Llc	Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
US9708604B2 (en)	2009-03-17	2017-07-18	Curna, Inc.	Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
KR20170072367A (ko)	2009-04-15	2017-06-26	노오쓰웨스턴 유니버시티	올리고뉴클레오티드 관능화된 나노입자의 전달
EP3524275A1 (de)	2009-04-22	2019-08-14	Massachusetts Institute Of Technology	Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
WO2010124231A2 (en)	2009-04-24	2010-10-28	The Board Of Regents Of The University Of Texas System	Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
WO2010127195A2 (en)	2009-05-01	2010-11-04	Curna, Inc.	Antisense oligonucleotides of hemoglobins
CA3042927C (en)	2009-05-05	2022-05-17	Arbutus Biopharma Corporation	Lipid compositions for the delivery of therapeutic agents
CA2760706C (en)	2009-05-05	2019-08-06	Alnylam Pharmaceuticals, Inc.	Methods of delivering oligonucleotides to immune cells
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
ES2609655T3 (es)	2009-05-06	2017-04-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
EP2430161A1 (de)	2009-05-15	2012-03-21	Yale University	Gemm-riboswitches, strukturbasierte verbindungskonstruktion mit gemm-riboswitches sowie verfahren und zusammensetzungen zur verwendung von und mit gemm-riboswitches
DK2432881T3 (en)	2009-05-18	2018-02-26	Curna Inc	TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
KR101703695B1 (ko)	2009-05-22	2017-02-08	큐알엔에이, 인크.	전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
KR101704988B1 (ko)	2009-05-28	2017-02-08	큐알엔에이, 인크.	항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
KR20220038506A (ko)	2009-06-10	2022-03-28	알닐람 파마슈티칼스 인코포레이티드	향상된 지질 조성물
ES2629339T3 (es)	2009-06-16	2017-08-08	Curna, Inc.	Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
WO2010148050A2 (en)	2009-06-16	2010-12-23	Curna, Inc.	Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
KR20220084437A (ko)	2009-06-17	2022-06-21	바이오젠 엠에이 인코포레이티드	대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
ES2618894T3 (es)	2009-06-24	2017-06-22	Curna, Inc.	Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
CN102482672B (zh)	2009-06-26	2016-11-09	库尔纳公司	通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
CA2769665A1 (en)	2009-08-05	2011-02-10	Opko Curna, Llc	Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
EP2462153B1 (de)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexosenukleinsäureanaloga
US9029338B2 (en)	2009-08-14	2015-05-12	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en)	2009-08-17	2012-06-21	Yale University	Methylation biomarkers and methods of use
CN102482671B (zh)	2009-08-25	2017-12-01	库尔纳公司	通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
JP5887270B2 (ja)	2009-09-02	2016-03-16	ジェネンテック，インコーポレイテッド	突然変異体ｓｍｏｏｔｈｅｎｅｄおよびその使用方法
RU2539772C2 (ru)	2009-10-22	2015-01-27	Дженентек, Инк.	Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
WO2011056687A2 (en)	2009-10-27	2011-05-12	Swift Biosciences, Inc.	Polynucleotide primers and probes
CN102666879B (zh)	2009-10-30	2016-02-24	西北大学	模板化的纳米缀合物
US20110110860A1 (en)	2009-11-02	2011-05-12	The Board Of Regents Of The University Of Texas System	Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
EP2496716A1 (de)	2009-11-03	2012-09-12	University Of Virginia Patent Foundation	Vielseitiges sichtbares verfahren für den nachweis von polymeranalyten
JP2013511285A (ja)	2009-11-23	2013-04-04	スイフト・バイオサイエンシズ・インコーポレイテツド	一本鎖標的分子を伸長させるデバイス
TWI507524B (zh)	2009-11-30	2015-11-11	建南德克公司	診斷及治療腫瘤之組合物及方法
CA3044884A1 (en)	2009-12-07	2011-06-16	Arbutus Biopharma Corporation	Compositions for nucleic acid delivery
CA2782366A1 (en)	2009-12-16	2011-07-14	Opko Curna, Llc	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
US20130017223A1 (en)	2009-12-18	2013-01-17	The University Of British Columbia	Methods and compositions for delivery of nucleic acids
US8940708B2 (en)	2009-12-23	2015-01-27	Curna, Inc.	Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
EP2515947B1 (de)	2009-12-23	2021-10-06	CuRNA, Inc.	Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2
US8921334B2 (en)	2009-12-29	2014-12-30	Curna, Inc.	Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
ES2585829T3 (es)	2009-12-29	2016-10-10	Curna, Inc.	Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
US8946181B2 (en)	2010-01-04	2015-02-03	Curna, Inc.	Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
RU2612161C2 (ru)	2010-01-06	2017-03-02	Курна, Инк.	Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
NO2524039T3 (de)	2010-01-11	2018-04-28
US8779118B2 (en)	2010-01-11	2014-07-15	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
US20120321647A1 (en)	2010-01-12	2012-12-20	Yale University	Structured rna motifs and compounds and methods for their use
US20110177107A1 (en) *	2010-01-14	2011-07-21	Haplomics, Inc.	Predicting and reducing alloimmunogenicity of protein therapeutics
ES2671877T3 (es)	2010-01-25	2018-06-11	Curna, Inc.	Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
WO2011094580A2 (en)	2010-01-28	2011-08-04	Alnylam Pharmaceuticals, Inc.	Chelated copper for use in the preparation of conjugated oligonucleotides
US9198972B2 (en)	2010-01-28	2015-12-01	Alnylam Pharmaceuticals, Inc.	Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011097388A1 (en)	2010-02-03	2011-08-11	Alnylam Pharmaceuticals, Inc.	Selective inhibition of polyglutamine protein expression
US20130028889A1 (en)	2010-02-04	2013-01-31	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
WO2011103528A2 (en)	2010-02-22	2011-08-25	Opko Curna Llc	Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
AU2011221226A1 (en)	2010-02-23	2012-08-16	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
US20130101512A1 (en)	2010-03-12	2013-04-25	Chad A. Mirkin	Crosslinked polynucleotide structure
EP3210611B1 (de)	2010-03-12	2019-08-21	The Brigham and Women's Hospital, Inc.	Verfahren zur behandlung von gefässentzündungserkrankungen
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
US8889350B2 (en)	2010-03-26	2014-11-18	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
US9506057B2 (en)	2010-03-26	2016-11-29	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
WO2011120049A1 (en)	2010-03-26	2011-09-29	Integrated Dna Technologies, Inc.	Methods for enhancing nucleic acid hybridization
US20130281510A1 (en)	2010-03-29	2013-10-24	Kumamoto University	siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
WO2011123621A2 (en)	2010-04-01	2011-10-06	Alnylam Pharmaceuticals Inc.	2' and 5' modified monomers and oligonucleotides
EP3578657B1 (de)	2010-04-06	2024-03-20	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der cd274/pd-l1-genexpression
WO2011127337A2 (en)	2010-04-09	2011-10-13	Opko Curna Llc	Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2011133695A2 (en)	2010-04-20	2011-10-27	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
WO2011133868A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011133876A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9725479B2 (en)	2010-04-22	2017-08-08	Ionis Pharmaceuticals, Inc.	5′-end derivatives
WO2011139699A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139695A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139702A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	Modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
ES2625689T3 (es)	2010-04-29	2017-07-20	Ionis Pharmaceuticals, Inc.	Modulación de la expresión de transtiretina
CN102958941A (zh)	2010-05-03	2013-03-06	霍夫曼-拉罗奇有限公司	用于肿瘤诊断和治疗的组合物和方法
RU2693462C2 (ru)	2010-05-03	2019-07-03	Курна, Инк.	Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
WO2011150226A1 (en)	2010-05-26	2011-12-01	Landers James P	Method for detecting nucleic acids based on aggregate formation
WO2011150005A2 (en)	2010-05-26	2011-12-01	Opko Curna Llc	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
EP3456827A3 (de)	2010-06-02	2019-05-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von leberfibrose
US9476101B2 (en)	2010-06-07	2016-10-25	Firefly Bioworks, Inc.	Scanning multifunctional particles
US8957200B2 (en)	2010-06-07	2015-02-17	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8846637B2 (en)	2010-06-08	2014-09-30	Isis Pharmaceuticals, Inc.	Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156713A1 (en)	2010-06-11	2011-12-15	Vanderbilt University	Multiplexed interferometric detection system and method
WO2011163121A1 (en)	2010-06-21	2011-12-29	Alnylam Pharmaceuticals, Inc.	Multifunctional copolymers for nucleic acid delivery
US9168297B2 (en)	2010-06-23	2015-10-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (NRG-1)
CN103068982B (zh)	2010-07-14	2017-06-09	库尔纳公司	通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
ES2756326T3 (es)	2010-07-19	2020-04-27	Ionis Pharmaceuticals Inc	Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
WO2012016184A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
WO2012016188A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
WO2012021554A1 (en)	2010-08-09	2012-02-16	Yale University	Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
CA2809457C (en)	2010-09-07	2019-07-30	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
WO2012044992A2 (en)	2010-09-30	2012-04-05	Agency For Science, Technology And Research (A*Star)	Methods and reagents for detection and treatment of esophageal metaplasia
US8481680B2 (en)	2010-10-05	2013-07-09	Genentech, Inc.	Mutant smoothened and methods of using the same
US8993533B2 (en)	2010-10-06	2015-03-31	Curna, Inc.	Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
WO2012048113A2 (en)	2010-10-07	2012-04-12	The General Hospital Corporation	Biomarkers of cancer
CN103180445B (zh)	2010-10-22	2018-02-16	库尔纳公司	通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
EP2633052B1 (de)	2010-10-27	2018-04-11	CuRNA, Inc.	Behandlung ifrd1-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen ifrd1
US9339513B2 (en)	2010-11-09	2016-05-17	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP3702460A1 (de)	2010-11-12	2020-09-02	The General Hospital Corporation	Polycombassoziierte nichtcodierende rnas
EP3521451A1 (de)	2010-11-17	2019-08-07	Ionis Pharmaceuticals, Inc.	Modulation von alpha-synuklein-expression
US8987225B2 (en)	2010-11-23	2015-03-24	Curna, Inc.	Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
US9193973B2 (en)	2010-12-10	2015-11-24	Alynylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (EPO) production
WO2012079046A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
US9999673B2 (en)	2011-01-11	2018-06-19	Alnylam Pharmaceuticals, Inc.	PEGylated lipids and their use for drug delivery
EP2663323B1 (de)	2011-01-14	2017-08-16	The General Hospital Corporation	Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
DK2670411T3 (da)	2011-02-02	2019-05-13	Excaliard Pharmaceuticals Inc	Antisense-forbindelser rettet mod bindevævsvækstfaktor (CTGF) til anvendelse i en fremgangsmåde til behandling af keloider eller hypertrofiske ar
CN103391777A (zh)	2011-02-02	2013-11-13	普林斯顿大学理事会	作为病毒产生调节剂的去乙酰化酶调节剂
AU2012212023B9 (en)	2011-02-03	2017-01-12	Mirna Therapeutics, Inc.	Synthetic mimics of miR-34
US9222085B2 (en)	2011-02-03	2015-12-29	Mirna Therapeutics, Inc.	Synthetic mimics of MIR-124
US10017764B2 (en)	2011-02-08	2018-07-10	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US20140044644A1 (en)	2011-02-21	2014-02-13	University Of Zurich	Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
KR102104401B1 (ko)	2011-03-29	2020-04-27	알닐람 파마슈티칼스 인코포레이티드	Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
US10086043B2 (en)	2011-04-03	2018-10-02	The General Hospital Corporation	Efficient protein expression in vivo using modified RNA (MOD-RNA)
CN103649333B (zh)	2011-04-20	2017-02-15	梅撒生物科技公司	用于核酸检测和鉴定的集成装置
WO2012149154A1 (en)	2011-04-26	2012-11-01	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2012170771A1 (en)	2011-06-09	2012-12-13	Curna, Inc.	Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
WO2012170945A2 (en)	2011-06-10	2012-12-13	Isis Pharmaceuticals, Inc.	Methods for modulating kallikrein (klkb1) expression
EP2723756B1 (de)	2011-06-21	2020-03-11	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression von apolipoprotein-c-iii (apoc3)-genen
EP2723351B1 (de)	2011-06-21	2018-02-14	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
CA2839573A1 (en)	2011-06-21	2012-12-27	Alnylam Pharmaceuticals, Inc.	Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
US20140235693A1 (en)	2011-06-23	2014-08-21	Alnylam Pharmaceuticals, Inc.	Serpina1 sirnas: compositions of matter and methods of treatment
AU2012275096B2 (en)	2011-06-29	2016-02-04	Ionis Pharmaceuticals, Inc.	Methods for modulating kallikrein (KLKB1) expression
JP2014526887A (ja)	2011-08-01	2014-10-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	造血幹細胞移植の成功率を改善する方法
US20140303235A1 (en)	2011-08-11	2014-10-09	Isis Pharmaceuticals, Inc.	Linkage modified gapped oligomeric compounds and uses thereof
CN104023749B (zh)	2011-09-14	2019-12-17	西北大学	能穿过血脑屏障的纳米缀合物
HK1200484A1 (zh)	2011-09-14	2015-08-07	Translate Bio Ma, Inc.	多聚寡核苷酸化合物
WO2013040548A2 (en)	2011-09-17	2013-03-21	Yale University	Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
JP6250543B2 (ja)	2011-09-27	2017-12-20	アルニラム・ファーマシューティカルズ・インコーポレーテッド	ジ脂肪族置換ｐｅｇ化脂質
EP2766482B1 (de)	2011-10-11	2016-12-07	The Brigham and Women's Hospital, Inc.	Mikro-rnas in neurodegenerativen erkrankungen
PE20141562A1 (es)	2011-10-14	2014-11-12	Genentech Inc	Anticuerpos anti-htra1 y metodos de uso
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
ES2923757T3 (es)	2011-12-16	2022-09-30	Modernatx Inc	Composiciones de ARNm modificado
ES2673960T3 (es)	2011-12-22	2018-06-26	Ionis Pharmaceuticals, Inc.	Métodos para modular la expresión de un transcrito-1 de adenocarcinoma en pulmón asociado a metástasis (MALAT-1)
EP3330278A1 (de)	2012-02-08	2018-06-06	Ionis Pharmaceuticals, Inc.	Modulation von rna durch wiederholtes targeting
WO2013151664A1 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins
LT2825672T (lt)	2012-03-13	2019-06-10	Swift Biosciences, Inc.	Būdai ir kompozicijos, skirti valdomam pagal dydį substrato polinukleotidų homopolimeriniam uodegų formavimui su nukleorūgščių polimeraze
ES2694592T3 (es)	2012-03-15	2018-12-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
US9610362B2 (en)	2012-03-16	2017-04-04	Valerion Therapeutics, Llc	Antisense conjugates for decreasing expression of DMPK
US9340784B2 (en)	2012-03-19	2016-05-17	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating alpha-1-antitrypsin expression
CN104411338A (zh)	2012-04-02	2015-03-11	现代治疗公司	用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
EP2850092B1 (de)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclische nukleinsäureanaloga
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
CN107083385A (zh)	2012-04-20	2017-08-22	艾珀特玛治疗公司	产热的miRNA调节剂
EP3336189A1 (de)	2012-04-20	2018-06-20	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
EP2841572B1 (de)	2012-04-27	2019-06-19	Duke University	Genetische korrektur mutierter gene
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
CN104583398A (zh)	2012-05-16	2015-04-29	Rana医疗有限公司	用于调节基因表达的组合物和方法
JP2015523854A (ja)	2012-05-16	2015-08-20	ラナセラピューティクスインコーポレイテッド	Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
WO2013177248A2 (en)	2012-05-22	2013-11-28	Isis Pharmaceuticals, Inc.	Modulation of enhancer rna mediated gene expression
ES2809199T3 (es)	2012-06-25	2021-03-03	Ionis Pharmaceuticals Inc	Modulación de la expresión de UBE3A-ATS
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
EP3693460A1 (de)	2012-07-27	2020-08-12	Ionis Pharmaceuticals, Inc.	Modulation von mit dem reninangiotensinsystem (ras) assoziierten erkrankungen durch angiotensinogen
WO2014022852A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
WO2014028739A1 (en)	2012-08-15	2014-02-20	Isis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
WO2014045126A2 (en)	2012-09-18	2014-03-27	Uti Limited Partnership	Treatment of pain by inhibition of usp5 de-ubiquitinase
US9175291B2 (en)	2012-10-11	2015-11-03	Isis Pharmaceuticals Inc.	Modulation of androgen receptor expression
WO2014059364A1 (en)	2012-10-11	2014-04-17	Isis Pharmaceuticals, Inc.	Methods of treating kennedy's disease
US9695418B2 (en)	2012-10-11	2017-07-04	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
HK1214293A1 (zh)	2012-10-26	2016-07-22	Geron Corporation	C-myc反义寡核苷酸和利用其治疗细胞增殖性疾病的方法
EP2914621B1 (de)	2012-11-05	2023-06-07	Foundation Medicine, Inc.	Neuartige ntrk1-fusionsmoleküle und verwendungen davon
EP4223770A3 (de)	2012-11-05	2023-10-18	Foundation Medicine, Inc.	Neuartige fusionsmoleküle und verwendungen davon
PT2922554T (pt)	2012-11-26	2022-06-28	Modernatx Inc	Arn modificado nas porções terminais
US10272163B2 (en)	2012-12-07	2019-04-30	The Regents Of The University Of California	Factor VIII mutation repair and tolerance induction
EP3434774A1 (de)	2013-01-17	2019-01-30	ModernaTX, Inc.	Signal-sensor-polynukleotide zur veränderung zellulärer phänotypen
CA2898326C (en)	2013-01-18	2022-05-17	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
DK2951191T3 (en)	2013-01-31	2019-01-14	Ionis Pharmaceuticals Inc	PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS
KR20200123263A (ko)	2013-02-14	2020-10-28	아이오니스 파마수티컬즈, 인코포레이티드	지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
EP2961853B1 (de)	2013-02-28	2018-09-19	The Board of Regents of The University of Texas System	Verfahren zur klassifizierung einer krebserkrankung als anfälligkeit für tmepai-gerichtete therapien und zur heilung solcher krebserkrankungen
US20160024181A1 (en)	2013-03-13	2016-01-28	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
US10258698B2 (en)	2013-03-14	2019-04-16	Modernatx, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
PT2970974T (pt)	2013-03-14	2017-11-29	Alnylam Pharmaceuticals Inc	Composições de irna de componente do complemento c5 e métodos para a sua utilização
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
EP2978446B1 (de)	2013-03-27	2020-03-04	The General Hospital Corporation	Anti-cd33 antikörper zur behandlung von morbus alzheimer
EP4286517A3 (de)	2013-04-04	2024-03-13	President and Fellows of Harvard College	Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen
WO2014172698A1 (en)	2013-04-19	2014-10-23	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
PL2992098T3 (pl)	2013-05-01	2019-09-30	Ionis Pharmaceuticals, Inc.	Kompozycje i sposoby modulowania ekspresji hbv i ttr
AU2014268529C1 (en)	2013-05-22	2020-10-01	Alnylam Pharmaceuticals, Inc.	TMPRSS6 iRNA compositions and methods of use thereof
TWI664187B (zh)	2013-05-22	2019-07-01	阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
US20160113911A1 (en)	2013-06-06	2016-04-28	The General Hospital Corporation	Methods and compositions for the treatment of cancer
DK3007704T3 (da)	2013-06-13	2021-03-29	Antisense Therapeutics Ltd	Kombinationsterapi til akromegali
EP3656386A1 (de)	2013-06-21	2020-05-27	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation der apolipoprotein-c-iii-expression zur verbesserung eines diabetischen profils
JP6487913B2 (ja)	2013-07-02	2019-03-20	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	成長ホルモン受容体のモジュレータ
PL3019619T3 (pl)	2013-07-11	2022-01-10	Modernatx, Inc.	Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
WO2015017694A1 (en) *	2013-07-31	2015-02-05	Regents Of The University Of California	Dna double-write/double binding identity
AU2014306271A1 (en)	2013-08-08	2016-03-24	The Scripps Research Institute	A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
US9670492B2 (en)	2013-08-28	2017-06-06	Ionis Pharmaceuticals, Inc.	Modulation of prekallikrein (PKK) expression
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
CA2923029A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Chimeric polynucleotides
PL3043827T3 (pl)	2013-09-13	2020-03-31	Ionis Pharmaceuticals, Inc.	Modulatory czynnika b dopełniacza
MX385871B (es)	2013-10-02	2025-03-18	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen lect2.
KR20160067219A (ko)	2013-10-03	2016-06-13	모더나 세라퓨틱스, 인코포레이티드	저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015051318A1 (en)	2013-10-04	2015-04-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the alas1 gene
EP3055426B1 (de)	2013-10-09	2019-06-19	The United States of America as represented by The Secretary Department of Health and Human Services	Nachweis von hepatitis delta virus (hdv) zur diagnose und behandlung von sjögren-syndrom und lymphom
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
EP3502270B1 (de)	2013-10-21	2020-03-18	The General Hospital Corporation	Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und mit der behandlung von krebs
US9758546B2 (en)	2013-10-21	2017-09-12	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
US10301622B2 (en)	2013-11-04	2019-05-28	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
SI3071696T1 (sl)	2013-11-22	2019-11-29	Mina Therapeutics Ltd	C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
WO2015126502A2 (en)	2013-12-03	2015-08-27	Northwestern University	Liposomal particles, methods of making same and uses thereof
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
US10385388B2 (en)	2013-12-06	2019-08-20	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
WO2015089368A2 (en)	2013-12-12	2015-06-18	Alnylam Pharmaceuticals, Inc.	Complement component irna compositions and methods of use thereof
AU2014364520B2 (en)	2013-12-20	2020-01-02	The General Hospital Corporation	Methods and assays relating to circulating tumor cells
PL3087183T3 (pl)	2013-12-24	2021-01-11	Ionis Pharmaceuticals, Inc.	Modulacja ekspresji białka angiopoetynopodobnego 3
US20170044232A1 (en)	2014-02-04	2017-02-16	Genentech, Inc.	Mutant smoothened and methods of using the same
EP3105331B1 (de)	2014-02-11	2021-06-23	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
EP3119789B1 (de)	2014-03-17	2020-04-22	Ionis Pharmaceuticals, Inc.	Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
SI3119888T1 (sl)	2014-03-19	2021-11-30	Ionis Pharmaceuticals, Inc.	Sestavki za moduliranje izražanja ataksina 2
WO2015143245A1 (en)	2014-03-19	2015-09-24	Isis Pharmaceuticals, Inc.	Methods for modulating ataxin 2 expression
HUE050704T2 (hu)	2014-04-01	2020-12-28	Biogen Ma Inc	Összetételek a SOD-1 expressziójának modulálására
EP3129493B1 (de)	2014-04-09	2021-07-07	The Scripps Research Institute	Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern
US20170044538A1 (en)	2014-04-17	2017-02-16	Biogen Ma Inc.	Compositions and Methods for Modulation of SMN2 Splicing in a Subject
WO2015164693A1 (en)	2014-04-24	2015-10-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015168589A2 (en)	2014-05-01	2015-11-05	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating angiopoietin-like 3 expression
HUE052709T2 (hu)	2014-05-01	2021-05-28	Ionis Pharmaceuticals Inc	Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
EP3137115B1 (de)	2014-05-01	2020-10-14	Ionis Pharmaceuticals, Inc.	Verfahren zur synthese von reaktiven konjugatclustern
CR20160554A (es)	2014-05-01	2017-03-07	Ionis Pharmaceuticals Inc	Composiciones y métodos para modular la expresión del factor b del complemento
WO2015168618A2 (en)	2014-05-01	2015-11-05	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating growth hormone receptor expression
WO2015171918A2 (en)	2014-05-07	2015-11-12	Louisiana State University And Agricultural And Mechanical College	Compositions and uses for treatment thereof
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
SG11201609376SA (en)	2014-05-22	2016-12-29	Alnylam Pharmaceuticals Inc	Angiotensinogen (agt) irna compositions and methods of use thereof
JP2017518307A (ja)	2014-06-02	2017-07-06	チルドレンズメディカルセンターコーポレーション	免疫調節のための方法および組成物
EP4039807A1 (de)	2014-06-10	2022-08-10	Erasmus University Rotterdam Medical Center	Zur behandlung der pompe-krankheit nützliche antisense-oligonukleotide
EP3161159B1 (de)	2014-06-25	2020-08-05	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
WO2016011226A1 (en)	2014-07-16	2016-01-21	Moderna Therapeutics, Inc.	Chimeric polynucleotides
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
EP3171895A1 (de)	2014-07-23	2017-05-31	Modernatx, Inc.	Modifizierte polynukleotide zur herstellung von intrabodys
JP7081923B2 (ja)	2014-07-31	2022-06-07	ユーエイビーリサーチファンデーション	アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
EP3183007B1 (de)	2014-08-19	2020-06-17	Northwestern University	Therapeutika mit protein/oligonukleotid-kernschalennanopartikeln
KR102410072B1 (ko)	2014-08-29	2022-06-20	알닐람 파마슈티칼스 인코포레이티드	트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
US10385343B2 (en)	2014-08-29	2019-08-20	Children's Medical Center Corporation	Methods and compositions for the treatment of cancer
WO2016040748A1 (en)	2014-09-12	2016-03-17	Ionis Pharmaceuticals, Inc.	Compositions and methods for detection of smn protein in a subject and treatment of a subject
WO2016040589A1 (en)	2014-09-12	2016-03-17	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
US10533172B2 (en)	2014-09-18	2020-01-14	The University Of British Columbia	Allele-specific therapy for huntington disease haplotypes
EP3663403A1 (de)	2014-09-26	2020-06-10	University of Massachusetts	Rna-modulierende stoffe
TWI864340B (zh)	2014-10-10	2024-12-01	美商艾爾妮蘭製藥公司	用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3904519A1 (de)	2014-10-30	2021-11-03	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
TWI769565B (zh)	2014-11-10	2022-07-01	美商阿尼拉製藥公司	Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
MA40844A (fr)	2014-11-10	2017-09-20	Glaxosmithkline Ip No 2 Ltd	Compositions pharmaceutiques à action prolongée pour l'hépatite c
US10308937B2 (en)	2014-11-10	2019-06-04	Glaxosmithkline Intellectual Property (No. 2) Limited	Combination long acting compositions and methods for Hepatitis C
WO2016081444A1 (en)	2014-11-17	2016-05-26	Alnylam Pharmaceuticals, Inc.	Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016081911A2 (en)	2014-11-21	2016-05-26	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016086104A1 (en)	2014-11-25	2016-06-02	Ionis Pharmaceuticals, Inc.	Modulation of ube3a-ats expression
AU2015360794B2 (en)	2014-12-08	2021-07-08	The Board Of Regents Of The University Of Texas System	Lipocationic polymers and uses thereof
US20170369872A1 (en)	2014-12-18	2017-12-28	Alnylam Pharmaceuticals, Inc.	Reversir tm compounds
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en)	2015-01-06	2020-10-06	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
US10538763B2 (en)	2015-01-16	2020-01-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of DUX4
WO2016118812A1 (en)	2015-01-23	2016-07-28	Vanderbilt University	A robust interferometer and methods of using same
US10676726B2 (en)	2015-02-09	2020-06-09	Duke University	Compositions and methods for epigenome editing
JP2018510621A (ja)	2015-02-13	2018-04-19	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
US10450342B2 (en)	2015-02-23	2019-10-22	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
US12129471B2 (en)	2015-02-23	2024-10-29	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of human genetic diseases including hemoglobinopathies
MX391217B (es)	2015-02-26	2025-03-21	Ionis Pharmaceuticals Inc	Moduladores de rodopsina p23h con especificidad de alelo.
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
BR112017020750A2 (en)	2015-03-27	2018-06-26	President And Fellows Of Harvard College	modified t-cells and methods of producing and using them
CN107429250B (zh)	2015-04-03	2022-03-01	Ionis制药公司	用于调节tmprss6表达的化合物和方法
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
WO2016164746A1 (en)	2015-04-08	2016-10-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
WO2016168592A2 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating c9orf72 expression
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
AU2016253147B2 (en)	2015-04-24	2021-07-22	Mesa Biotech, Inc.	Fluidic test cassette
EP3307316A1 (de)	2015-06-12	2018-04-18	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
CN108139375A (zh)	2015-06-26	2018-06-08	贝斯以色列女执事医疗中心股份有限公司	靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
WO2017004243A1 (en)	2015-06-29	2017-01-05	Caris Science, Inc.	Therapeutic oligonucleotides
US10494632B2 (en)	2015-07-10	2019-12-03	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
CA3205381A1 (en)	2015-07-17	2017-01-26	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
US10941176B2 (en)	2015-07-28	2021-03-09	Caris Science, Inc.	Therapeutic oligonucleotides
WO2017021961A1 (en)	2015-08-04	2017-02-09	Yeda Research And Development Co. Ltd.	Methods of screening for riboswitches and attenuators
US10889813B2 (en)	2015-09-02	2021-01-12	Alnylam Pharmaceuticals, Inc.	Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
KR102764250B1 (ko)	2015-09-14	2025-02-07	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	지질양이온성 덴드리머 및 이의 용도
WO2017064546A1 (en)	2015-09-24	2017-04-20	Crispr Therapeutics Ag	Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
WO2017053781A1 (en)	2015-09-25	2017-03-30	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating ataxin 3 expression
MX392014B (es)	2015-10-08	2025-03-21	Ionis Pharmaceuticals Inc	Composiciones y métodos para modular la expresión de angiotensinógeno.
WO2017066497A2 (en)	2015-10-13	2017-04-20	Duke University	Genome engineering with type i crispr systems in eukaryotic cells
EP4279084B1 (de)	2015-10-28	2025-06-11	Vertex Pharmaceuticals Inc.	Materialien und verfahren zur behandlung von duchenne-muskeldystrophie
BR112018007703A2 (pt)	2015-10-30	2018-11-06	Genentech Inc	anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
EP3370734B1 (de)	2015-11-05	2023-01-04	Children's Hospital Los Angeles	Antisense-oligo zur verwendung bei der behandlung von akuter myeloischer leukämie
US11866727B2 (en)	2015-11-06	2024-01-09	Crispr Therapeutics Ag	Materials and methods for treatment of glycogen storage disease type 1A
AU2016349625B2 (en)	2015-11-06	2022-07-07	Ionis Pharmaceuticals, Inc.	Modulating apolipoprotein (a) expression
CA3005878A1 (en)	2015-11-19	2017-05-26	The Brigham And Women's Hospital, Inc.	Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
US12214054B2 (en)	2015-11-30	2025-02-04	Duke University	Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
WO2017093804A2 (en)	2015-12-01	2017-06-08	Crispr Therapeutics Ag	Materials and methods for treatment of alpha-1 antitrypsin deficiency
EP3389670A4 (de)	2015-12-04	2020-01-08	Ionis Pharmaceuticals, Inc.	Verfahren zur behandlung von brustkrebs
US10993995B2 (en)	2015-12-07	2021-05-04	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for pompe disease
IL308717A (en)	2015-12-07	2024-01-01	Genzyme Corp	Methods and compositions for treating a serpinc1-associated disorder
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
CA3009308A1 (en)	2015-12-23	2017-06-29	Chad Albert COWAN	Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
WO2017117496A1 (en)	2015-12-31	2017-07-06	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
EP3400300A4 (de)	2016-01-05	2019-08-07	Ionis Pharmaceuticals, Inc.	Verfahren zur reduzierung der lrrk2-expression
EP3408649B1 (de)	2016-01-29	2023-06-14	Vanderbilt University	Interferometrie mit antwortfunktion in freier lösung
EP3411078A1 (de)	2016-02-02	2018-12-12	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn-syndrom
AU2017213826A1 (en)	2016-02-04	2018-08-23	Curis, Inc.	Mutant smoothened and methods of using the same
WO2017141109A1 (en)	2016-02-18	2017-08-24	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
EP4512904A3 (de)	2016-02-25	2025-04-09	The Brigham and Women's Hospital, Inc.	Behandlungsverfahren für fibrose-targeting-smoc2
US11083799B2 (en)	2016-03-16	2021-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
CA3013799A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Methods of modulating keap1
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
AU2017235661B2 (en)	2016-03-18	2023-06-08	Caris Science, Inc.	Oligonucleotide probes and uses thereof
EP3443081A4 (de)	2016-04-13	2019-10-30	Duke University	Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
JP6974349B2 (ja)	2016-04-18	2021-12-01	クリスパーセラピューティクスアクチェンゲゼルシャフト	ヘモグロビン異常症の処置のための材料及び方法
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
CN114656378A (zh)	2016-05-16	2022-06-24	得克萨斯州大学系统董事会	阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
IL298701B2 (en)	2016-05-25	2024-03-01	Caris Science Inc	Oligonucleotide probes and uses thereof
EP3469083A1 (de)	2016-06-10	2019-04-17	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
AU2017286811A1 (en)	2016-06-17	2018-11-22	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
EP3475295B1 (de)	2016-06-24	2022-08-10	The Scripps Research Institute	Neuartiger nukleosid-triphosphat-transporter und verwendungen davon
WO2018002762A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
CA3029119A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
US11427838B2 (en)	2016-06-29	2022-08-30	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
EP4650364A3 (de)	2016-07-06	2026-01-21	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von schmerzbedingten erkrankungen
EP3481857B1 (de)	2016-07-06	2026-02-11	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von schmerzbedingten erkrankungen
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
AU2017296195A1 (en)	2016-07-11	2019-01-24	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
JP7490211B2 (ja)	2016-07-19	2024-05-27	デュークユニバーシティ	Ｃｐｆ１に基づくゲノム編集の治療適用
US20190247436A1 (en)	2016-07-21	2019-08-15	Maxcyte, Inc.	Methods and compositions for modifying genomic dna
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
WO2018067900A1 (en)	2016-10-06	2018-04-12	Ionis Pharmaceuticals, Inc.	Method of conjugating oligomeric compounds
WO2018081817A2 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
TW202313978A (zh)	2016-11-23	2023-04-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
US11033570B2 (en)	2016-12-02	2021-06-15	Cold Spring Harbor Laboratory	Modulation of Lnc05 expression
CA3045667A1 (en)	2016-12-13	2018-06-21	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
TWI865997B (zh)	2016-12-16	2024-12-11	美商阿尼拉製藥公司	使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法
CA3049980A1 (en)	2017-01-23	2018-07-26	Regeneron Pharmaceuticals, Inc.	Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
AU2018224387B2 (en)	2017-02-22	2024-08-08	Crispr Therapeutics Ag	Compositions and methods for gene editing
EP3585899A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
WO2018154418A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
WO2018154439A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
WO2018154462A2 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
WO2018183969A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
EP3609521A4 (de)	2017-04-14	2021-06-16	University of Massachusetts	Targeting von zelltropismus-rezeptoren zur hemmung von infektionen durch das cytomegalovirus
WO2018195165A1 (en)	2017-04-18	2018-10-25	Alnylam Pharmaceuticals, Inc.	Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
WO2018193428A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
CA3059321A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
WO2018195486A1 (en)	2017-04-21	2018-10-25	The Broad Institute, Inc.	Targeted delivery to beta cells
BR112019023608A2 (pt)	2017-05-12	2020-05-26	Crispr Therapeutics Ag	Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US11060094B2 (en)	2017-05-19	2021-07-13	Band Therapeutics, Llc	Compositions and methods for the treatment of complications and disorders relating to Von Willebrand Factor
JP2020530442A (ja)	2017-07-10	2020-10-22	ジェンザイム・コーポレーション	血友病を有する対象の出血事象を処置するための方法および組成物
TWI821192B (zh)	2017-07-11	2023-11-11	美商新索思股份有限公司	非天然核苷酸之導入及其方法
CA3069868A1 (en)	2017-07-13	2019-01-17	Alnylam Pharmaceuticals Inc.	Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
JP2020526558A (ja)	2017-07-13	2020-08-31	ノースウェスタンユニバーシティ	オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
AU2018301829B2 (en)	2017-07-13	2024-08-01	Alnylam Pharmaceuticals, Inc.	Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression
IL321812A (en)	2017-08-03	2025-08-01	Synthorx Inc	Cytokine complexes for the treatment of autoimmune diseases
CA3071033A1 (en)	2017-08-18	2019-02-21	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019048645A1 (en)	2017-09-08	2019-03-14	Mina Therapeutics Limited	STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
US10517889B2 (en)	2017-09-08	2019-12-31	Ionis Pharmaceuticals, Inc.	Modulators of SMAD7 expression
WO2019048632A1 (en)	2017-09-08	2019-03-14	Mina Therapeutics Limited	STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
WO2019055460A1 (en)	2017-09-13	2019-03-21	The Children's Medical Center Corporation	COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRANSPOSON-ASSOCIATED DISEASES
EP3684931A1 (de)	2017-09-19	2020-07-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von transthyretin(ttr)-vermittelter amyloidose
US20220080055A9 (en)	2017-10-17	2022-03-17	Crispr Therapeutics Ag	Compositions and methods for gene editing for hemophilia a
MA50849A (fr)	2017-10-26	2020-09-02	Vertex Pharma	Substances et procédés pour le traitement d'hémoglobinopathies
CA3078971A1 (en)	2017-11-01	2019-05-09	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
MA50579A (fr)	2017-11-09	2020-09-16	Crispr Therapeutics Ag	Systèmes crispr/cas ou crispr/cpf1 à auto-inactivation (sin) et leurs utilisations
EP3710587A1 (de)	2017-11-16	2020-09-23	Alnylam Pharmaceuticals, Inc.	Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
EP3714055A1 (de)	2017-11-21	2020-09-30	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von autosomal-dominanter retinitis pigmentosa
EP3714053B1 (de)	2017-11-22	2025-12-31	The University of Chicago	Von chemischer sonde abhängige bewertung der proteinaktivität und verwendung davon
JP2021505587A (ja)	2017-12-05	2021-02-18	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｃｒｉｓｐｒ−ｃａｓ９改変ｃｄ３４＋ヒト造血幹・前駆細胞及びその使用
CA3084825A1 (en)	2017-12-14	2019-06-20	Crispr Therapeutics Ag	Novel rna-programmable endonuclease systems and their use in genome editing and other applications
WO2019126097A1 (en)	2017-12-18	2019-06-27	Alnylam Pharmaceuticals, Inc.	High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
AU2018393050A1 (en)	2017-12-21	2020-06-18	Bayer Healthcare Llc	Materials and methods for treatment of Usher Syndrome Type 2A
CA3084633A1 (en)	2017-12-21	2019-06-27	Crispr Therapeutics Ag	Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
JP7429642B2 (ja)	2017-12-29	2024-02-08	ザスクリプスリサーチインスティテュート	非天然塩基対組成物および使用の方法
WO2019140102A1 (en)	2018-01-10	2019-07-18	Translate Bio Ma, Inc.	Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
EP3737762A1 (de)	2018-01-12	2020-11-18	CRISPR Therapeutics AG	Zusammensetzungen und verfahren zur geneditierung von genen durch transferrin-targeting
CA3088522A1 (en)	2018-01-15	2019-07-18	Ionis Pharmaceuticals, Inc.	Modulators of dnm2 expression
US12509492B2 (en)	2018-01-19	2025-12-30	Duke University	Genome engineering with CRISPR-Cas systems in eukaryotes
US20190233816A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
MA51787A (fr)	2018-02-05	2020-12-16	Vertex Pharma	Substances et méthodes de traitement d'hémoglobinopathies
EP3749768A1 (de)	2018-02-05	2020-12-16	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
EP3752616A1 (de)	2018-02-16	2020-12-23	CRISPR Therapeutics AG	Zusammensetzungen und verfahren zur geneditierung durch targeting von fibrinogen-alpha
AU2019224159B2 (en)	2018-02-26	2025-05-29	Sanofi	IL-15 conjugates and uses thereof
WO2019169243A1 (en)	2018-03-02	2019-09-06	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-beta precursor protein
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
JP7550648B2 (ja)	2018-03-19	2024-09-13	クリスパーセラピューティクスアーゲー	新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
WO2019183440A1 (en)	2018-03-22	2019-09-26	Ionis Pharmaceuticals, Inc.	Methods for modulating fmr1 expression
CA3095134A1 (en)	2018-03-28	2019-10-03	Board Of Regents, The University Of Texas System	Identification of epigenetic alterations in dna isolated from exosomes
WO2019186514A2 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
EP3772928B1 (de)	2018-04-06	2025-02-26	Children's Medical Center Corporation	Zusammensetzungen und verfahren zur prägung der umprogrammierung und modulation von somatischen zellen
WO2019200172A1 (en)	2018-04-11	2019-10-17	Ionis Pharmaceuticals, Inc.	Modulators of ezh2 expression
US11566246B2 (en)	2018-04-12	2023-01-31	Mina Therapeutics Limited	SIRT1-saRNA compositions and methods of use
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
CA3091490A1 (en)	2018-04-27	2019-10-31	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Rapamycin resistant cells
CA3098623A1 (en)	2018-05-07	2019-11-14	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
IL277970B2 (en)	2018-05-09	2025-03-01	Ionis Pharmaceuticals Inc	Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease
JP2021522800A (ja)	2018-05-09	2021-09-02	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ａｔｘｎ３発現を低減するための化合物及び方法
EP3790893A4 (de)	2018-05-11	2022-03-16	University Of Massachusetts	Verfahren zur verbesserung der leptinempfindlichkeit zur behandlung von fettleibigkeit und diabetes
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
CA3103429A1 (en)	2018-06-14	2019-12-19	Don W. Cleveland	Compounds and methods for increasing stmn2 expression
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
WO2020018558A1 (en)	2018-07-17	2020-01-23	Aronora, Inc.	Methods for safely reducing thrombopoietin
AU2019310097A1 (en)	2018-07-25	2021-02-04	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing ATXN2 expression
WO2020036862A1 (en)	2018-08-13	2020-02-20	Alnylam Pharmaceuticals, Inc.	HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
AR115960A1 (es)	2018-08-16	2021-03-17	Alnylam Pharmaceuticals Inc	Composiciones y métodos para inhibir la expresión del gen lect2
CA3110661A1 (en)	2018-08-29	2020-03-05	University Of Massachusetts	Inhibition of protein kinases to treat friedreich ataxia
CN112912422A (zh)	2018-09-14	2021-06-04	西北大学	用dna编程蛋白质聚合
JP2022500003A (ja)	2018-09-18	2022-01-04	アルナイラムファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc.	ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法
WO2020068983A1 (en)	2018-09-25	2020-04-02	Co-Diagnostics, Inc.	Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
CA3114396A1 (en)	2018-09-28	2020-04-02	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
JP7520826B2 (ja)	2018-10-17	2024-07-23	クリスパー・セラピューティクス・アクチェンゲゼルシャフト	導入遺伝子を送達するための組成物および方法
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
TW202031284A (zh)	2018-11-08	2020-09-01	美商新索思股份有限公司	介白素10結合物及其用途
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
MX2021005758A (es)	2018-11-15	2021-09-21	Ionis Pharmaceuticals Inc	Moduladores de la expresión de irf5.
US12281305B2 (en)	2018-11-21	2025-04-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing prion expression
CA3121191A1 (en)	2018-11-28	2020-06-04	Crispr Therapeutics Ag	Optimized mrna encoding cas9 for use in lnps
EP3894559A4 (de)	2018-12-03	2023-04-05	Triplet Therapeutics, Inc.	Verfahren zur behandlung von störungen der trinukleotid-repeat-expansion im zusammenhang mit mlh3-aktivität
WO2020118259A1 (en)	2018-12-06	2020-06-11	Northwestern University	Protein crystal engineering through dna hybridization interactions
JP2022515744A (ja)	2018-12-20	2022-02-22	プラクシスプレシジョンメディシンズ，インコーポレイテッド	Ｋｃｎｔ１関連障害の治療のための組成物及び方法
PT4285929T (pt)	2018-12-20	2026-01-02	Humabs Biomed Sa	Terapêutica de combinação contra o vhb
CA3126933A1 (en)	2019-01-16	2020-07-23	Genzyme Corporation	Serpinc1 irna compositions and methods of use thereof
TW202214854A (zh)	2019-01-31	2022-04-16	美商Ionis製藥公司	Yap1表現之調節劑
MA54952A (fr)	2019-02-06	2022-05-11	Synthorx Inc	Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
SG11202108357PA (en)	2019-02-15	2021-08-30	Crispr Therapeutics Ag	Gene editing for hemophilia a with improved factor viii expression
WO2020171889A1 (en)	2019-02-19	2020-08-27	University Of Rochester	Blocking lipid accumulation or inflammation in thyroid eye disease
WO2020176771A1 (en)	2019-02-27	2020-09-03	Ionis Pharmaceuticals, Inc.	Modulators of malat1 expression
US12702719B2 (en)	2019-03-06	2026-08-11	Northwestern University	Hairpin-like oligonucleotide-conjugated spherical nucleic acid
US20220145274A1 (en)	2019-03-12	2022-05-12	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
WO2020191177A1 (en)	2019-03-21	2020-09-24	Sudhir Agrawal	Antisense oligonucleotides for allele specificity
TW202536179A (zh)	2019-03-29	2025-09-16	美商Ionis製藥公司	用於調節ube3a-ats之化合物及方法
TW202104595A (zh)	2019-03-29	2021-02-01	日商田邊三菱製藥股份有限公司	用來調節ｄｕｘ４的表現之化合物、方法及醫藥組成物
EP3953473A1 (de)	2019-04-12	2022-02-16	MiNA Therapeutics Limited	Sirt1-sarna-zusammensetzungen und verfahren zur verwendung
TWI887234B (zh)	2019-04-14	2025-06-21	美國公爵大學	治療杜興氏（ｄｕｃｈｅｎｎｅ）肌肉失養症之大型突變熱點之ａａｖ載體介導之刪除
WO2020232024A1 (en)	2019-05-13	2020-11-19	Vir Biotechnology, Inc.	Compositions and methods for treating hepatitis b virus (hbv) infection
WO2020236600A1 (en)	2019-05-17	2020-11-26	Alnylam Pharmaceuticals, Inc.	Oral delivery of oligonucleotides
WO2020243021A2 (en)	2019-05-24	2020-12-03	Foundation Medicine, Inc.	Ntrk fusion molecules and uses thereof
WO2020252262A1 (en)	2019-06-14	2020-12-17	The Scripps Research Institute	Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
PL3956450T3 (pl)	2019-07-26	2025-12-22	Ionis Pharmaceuticals, Inc.	Związki i sposoby modulowania gfap
EP4007812A1 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EP4013454A1 (de)	2019-08-15	2022-06-22	Synthorx, Inc.	Immunonkologische kombinationstherapien mit il-2-konjugaten
KR20220062517A (ko)	2019-08-15	2022-05-17	아이오니스 파마수티컬즈, 인코포레이티드	결합 변형된 올리고머 화합물 및 이의 용도
CN114585633A (zh)	2019-08-19	2022-06-03	米纳治疗有限公司	寡核苷酸缀合物组合物和使用方法
CA3148135A1 (en)	2019-08-23	2021-03-04	Carolina E. CAFFARO	Il-15 conjugates and uses thereof
US20220290152A1 (en)	2019-09-03	2022-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
WO2021050554A1 (en)	2019-09-10	2021-03-18	Synthorx, Inc.	Il-2 conjugates and methods of use to treat autoimmune diseases
US12319711B2 (en)	2019-09-20	2025-06-03	Northwestern University	Spherical nucleic acids with tailored and active protein coronae
US12503699B2 (en)	2019-10-04	2025-12-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing UGT1a1 gene expression
EP4045652A1 (de)	2019-10-18	2022-08-24	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
CA3158320A1 (en)	2019-10-22	2021-04-29	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof
US12378560B2 (en)	2019-10-29	2025-08-05	Northwestern University	Sequence multiplicity within spherical nucleic acids
US20230040920A1 (en)	2019-11-01	2023-02-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
WO2021087036A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
JP2022554272A (ja)	2019-11-04	2022-12-28	シンソークス，インコーポレイテッド	インターロイキン１０コンジュゲートおよびその使用
EP4055165A1 (de)	2019-11-06	2022-09-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon für die behandlung oder prävention ttr-assoziierter augenerkrankungen
WO2021092371A2 (en)	2019-11-06	2021-05-14	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
IL292865A (en)	2019-11-13	2022-07-01	Alnylam Pharmaceuticals Inc	Methods and preparations for the treatment of angiotensinogen-related disorder - (agt)
EP4061945A1 (de)	2019-11-22	2022-09-28	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
IL293824A (en)	2019-12-13	2022-08-01	Alnylam Pharmaceuticals Inc	Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them
CN115176007A (zh)	2019-12-16	2022-10-11	阿尔尼拉姆医药品有限公司	含类PATATIN磷脂酶结构域3(PNPLA3)iRNA组合物及其使用方法
WO2021122944A1 (en)	2019-12-18	2021-06-24	Alia Therapeutics Srl	Compositions and methods for treating retinitis pigmentosa
EP4058032A4 (de)	2019-12-19	2024-01-10	Entrada Therapeutics, Inc.	Zusammensetzungen zur verabreichung von antisense-verbindungen
US12503695B2 (en)	2020-01-27	2025-12-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	RAB13 and NET1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
PH12022552080A1 (en)	2020-02-10	2024-02-12	Alnylam Pharmaceuticals Inc	Compositions and methods for silencing vegf-a expression
CN115397989A (zh)	2020-02-18	2022-11-25	阿尔尼拉姆医药品有限公司	载脂蛋白C3(APOC3)iRNA组合物及其使用方法
AU2021225957A1 (en)	2020-02-28	2022-09-08	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating SMN2
CA3174708A1 (en)	2020-03-04	2021-09-10	Verve Therapeutics, Inc.	Compositions and methods for targeted rna delivery
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
AU2021232029A1 (en)	2020-03-06	2022-10-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of transthyretin (TTR)
MX2022011009A (es)	2020-03-06	2022-10-07	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) de ketohexocinasa (khk) y metodos de uso de las mismas.
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
US20230190785A1 (en)	2020-03-30	2023-06-22	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
EP4127134A4 (de)	2020-04-01	2024-07-31	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen mit alpha-2a-adrenergen rezeptor (adra2a) und verfahren zur verwendung davon
IL297121A (en)	2020-04-06	2022-12-01	Alnylam Pharmaceuticals Inc	Compositions and methods for silencing myoc expression
EP4133077A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
AU2021251754A1 (en)	2020-04-07	2022-11-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing SCN9A expression
EP4132951A4 (de)	2020-04-09	2025-06-11	Verve Therapeutics, Inc.	Chemisch modifizierte guide-rnas zur genomeditierung mit cas12b
JP7844347B2 (ja)	2020-04-27	2026-04-13	アルナイラムファーマシューティカルズ，インコーポレイテッド	アポリポタンパク質Ｅ（ＡｐｏＥ）ｉＲＮＡ剤組成物およびその使用方法
MX2022013606A (es)	2020-04-30	2023-01-16	Alnylam Pharmaceuticals Inc	Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
TWI901676B (zh)	2020-05-01	2025-10-21	美商Ionis製藥公司	調節ａｔｘｎ１之化合物及方法
JP7776420B2 (ja)	2020-05-12	2025-11-26	田辺三菱製薬株式会社	Ａｔａｘｉｎ３発現を調節するための化合物、方法及び医薬組成物
EP4150086A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
EP4150076A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
EP4150090A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
EP4150087A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
WO2021231691A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
WO2021231698A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
EP4150088A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
WO2021237097A1 (en)	2020-05-21	2021-11-25	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
MX2022014606A (es)	2020-05-22	2023-03-08	Wave Life Sciences Ltd	Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
US11408000B2 (en)	2020-06-03	2022-08-09	Triplet Therapeutics, Inc.	Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
JP2023530234A (ja)	2020-06-05	2023-07-14	ザ・ブロード・インスティテュート・インコーポレイテッド	新生物を治療するための組成物および方法
CN116075592A (zh)	2020-06-09	2023-05-05	阿尔尼拉姆医药品有限公司	用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
WO2021252557A1 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Rnai compositions and methods of use thereof for delivery by inhalation
AU2021292296A1 (en)	2020-06-18	2023-01-19	Alnylam Pharmaceuticals, Inc.	Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
BR112022026316A2 (pt)	2020-06-24	2023-03-07	Vir Biotechnology Inc	Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
WO2021263026A1 (en)	2020-06-25	2021-12-30	Synthorx, Inc.	Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
TW202216996A (zh)	2020-06-29	2022-05-01	美商Ionis製藥公司	調節ｐｌｐ１之化合物及方法
KR20230050336A (ko)	2020-07-10	2023-04-14	인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸)	뇌전증을 치료하기 위한 방법과 조성물
US20230257745A1 (en)	2020-07-10	2023-08-17	Alnylam Pharmaceuticals, Inc.	Circular siRNAs
MX2023001222A (es)	2020-07-28	2023-04-26	Ionis Pharmaceuticals Inc	Compuestos y metodos para reducir la expresion de app.
IL300258A (en)	2020-08-07	2023-03-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating SCN2A
CN116368226A (zh)	2020-09-04	2023-06-30	维乎医疗有限公司	用于加帽rna的组合物和方法
EP4217489A1 (de)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022070107A1 (en)	2020-09-30	2022-04-07	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis
EP4225917A1 (de)	2020-10-05	2023-08-16	Alnylam Pharmaceuticals, Inc.	G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
EP3978608A1 (de)	2020-10-05	2022-04-06	SQY Therapeutics	Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
EP4225376A1 (de)	2020-10-09	2023-08-16	Synthorx, Inc.	Immunonkologische kombinationstherapie mit il-2-konjugaten und pembrolizumab
IL301612A (en)	2020-10-09	2023-05-01	Synthorx Inc	Immuno oncology therapies with il-2 conjugates
CA3198823A1 (en)	2020-10-21	2022-04-28	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
EP4232582A1 (de)	2020-10-23	2023-08-30	Alnylam Pharmaceuticals, Inc.	Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
CN116761885A (zh)	2020-10-23	2023-09-15	斯克利普斯研究所	包含非天然核苷酸的多核苷酸的逆转录
CA3200595A1 (en)	2020-11-13	2022-05-19	Alnylam Pharmaceuticals, Inc.	Coagulation factor v (f5) irna compositions and methods of use thereof
KR20230108728A (ko)	2020-11-18	2023-07-18	아이오니스 파마수티컬즈, 인코포레이티드	앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
WO2022119873A1 (en)	2020-12-01	2022-06-09	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
AR124408A1 (es)	2020-12-18	2023-03-22	Ionis Pharmaceuticals Inc	Compuestos y métodos para modular el factor xii
KR20230135585A (ko)	2020-12-23	2023-09-25	플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨	변형된 trem의 조성물 및 이의 용도
US20240343746A1 (en)	2020-12-31	2024-10-17	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
US20240336914A1 (en)	2020-12-31	2024-10-10	Alnylam Pharmaceuticals, Inc.	2'-modified nucleoside based oligonucleotide prodrugs
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202302148A (zh)	2021-02-12	2023-01-16	美商欣爍克斯公司	使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
EP4291654A2 (de)	2021-02-12	2023-12-20	Alnylam Pharmaceuticals, Inc.	Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen
WO2022174101A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Skin cancer combination therapy with il-2 conjugates and cemiplimab
WO2022183006A1 (en)	2021-02-25	2022-09-01	Mayo Foundation For Medical Education And Research	Compounds for programmable protein degradation and methods of use for the disease treatment
WO2022182864A1 (en)	2021-02-25	2022-09-01	Alnylam Pharmaceuticals, Inc.	Prion protein (prnp) irna compositions and methods and methods of use thereof
CA3211059A1 (en)	2021-02-26	2022-09-01	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
BR112023017737A2 (pt)	2021-03-04	2023-10-03	Alnylam Pharmaceuticals Inc	Composições de irna de angiopoietina-semelhantes 3 (angptl3) e métodos de uso das mesmas
EP4304640A1 (de)	2021-03-12	2024-01-17	Northwestern University	Antivirale impfstoffe mit kugelförmigen nukleinsäuren
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
US20240175033A1 (en)	2021-03-26	2024-05-30	Mina Therapeutics Limited	TMEM173 saRNA Compositions and Methods of Use
BR112023019981A2 (pt)	2021-03-29	2023-12-12	Alnylam Pharmaceuticals Inc	Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
KR20240009393A (ko)	2021-03-31	2024-01-22	엔트라다 테라퓨틱스, 인크.	사이클릭 세포 침투 펩티드
EP4314293A1 (de)	2021-04-01	2024-02-07	Alnylam Pharmaceuticals, Inc.	Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
AU2022261124A1 (en)	2021-04-22	2023-10-05	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating cancer
CA3216106A1 (en)	2021-04-26	2022-11-03	Alnylam Pharmaceuticals, Inc.	Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
EP4330396A1 (de)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
JP2024518374A (ja)	2021-05-03	2024-05-01	アルナイラムファーマシューティカルズ，インコーポレイテッド	トランスサイレチン（ｔｔｒ）媒介性アミロイドーシスを治療するための組成物および方法
US20250051393A1 (en)	2021-05-10	2025-02-13	Entrada Therapeutics, Inc.	Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
JP2024518476A (ja)	2021-05-10	2024-05-01	エントラーダセラピューティクス，インコーポレイティド	ｍＲＮＡスプライシングを調節するための組成物及び方法
IL308353A (en)	2021-05-10	2024-01-01	Entrada Therapeutics Inc	Compositions and methods for modulating tissue distribution of intracellular therapies
JP2024522068A (ja)	2021-05-18	2024-06-11	アルナイラムファーマシューティカルズ，インコーポレイテッド	ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法
US20240263177A1 (en)	2021-05-20	2024-08-08	Korro Bio, Inc.	Methods and Compositions for Adar-Mediated Editing
MX2023014008A (es)	2021-05-27	2023-12-11	Alnylam Pharmaceuticals Inc	Composiciones y metodos para silenciar la expresion de anhidrasa carbonica 2.
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
WO2022256395A1 (en)	2021-06-02	2022-12-08	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2022256534A1 (en)	2021-06-03	2022-12-08	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
MX2023014168A (es)	2021-06-04	2024-02-27	Alnylam Pharmaceuticals Inc	Marco de lectura abierto 72 del cromosoma humano 9 (c9orf72) composiciones de agente de arni y metodos de uso de este.
JP2024523000A (ja)	2021-06-08	2024-06-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	シュタルガルト病及び／又は網膜結合タンパク質４（ｒｂｐ４）関連障害を治療又は予防するための組成物及び方法
MX2023014774A (es)	2021-06-11	2024-01-15	Bayer Ag	Nuevos sistemas de endonucleasas programables de arn tipo v.
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
US11753644B2 (en)	2021-06-18	2023-09-12	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing IFNAR1 expression
AU2022298774A1 (en)	2021-06-23	2023-12-14	Entrada Therapeutics, Inc.	Antisense compounds and methods for targeting cug repeats
WO2023278410A1 (en)	2021-06-29	2023-01-05	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
IL309296A (en)	2021-06-30	2024-02-01	Alnylam Pharmaceuticals Inc	Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
WO2023283403A2 (en)	2021-07-09	2023-01-12	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
JP2024528659A (ja)	2021-07-19	2024-07-30	アルナイラムファーマシューティカルズ，インコーポレイテッド	非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物
IL309897A (en)	2021-07-21	2024-03-01	Alnylam Pharmaceuticals Inc	Target gene IRNA compositions associated with a metabolic disorder and methods of using them
TW202325312A (zh)	2021-07-23	2023-07-01	美商艾拉倫製藥股份有限公司	β－鏈蛋白（ＣＴＮＮＢ１）ｉＲＮＡ組成物及其使用方法
JP2024529437A (ja)	2021-07-29	2024-08-06	アルナイラムファーマシューティカルズ，インコーポレイテッド	３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
EP4380576A4 (de)	2021-08-03	2026-04-29	Verve Therapeutics Inc	Zusammensetzungen und verfahren zur gezielten rna-abgabe
AR126675A1 (es)	2021-08-03	2023-11-01	Alnylam Pharmaceuticals Inc	COMPOSICIONES DE ARNi CONTRA LA TRANSTIRRETINA (TTR) Y SUS MÉTODOS DE USO
CA3228255A1 (en)	2021-08-04	2023-02-09	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing angiotensinogen (agt)
CN118076737A (zh)	2021-08-13	2024-05-24	阿尔尼拉姆医药品有限公司	因子XII（F12）iRNA组合物及其使用方法
TW202325311A (zh)	2021-08-31	2023-07-01	美商艾拉倫製藥公司	誘導細胞死亡之DFFA樣效應子B (CIDEB) iRNA組合物及其使用方法
EP4395829A1 (de)	2021-09-01	2024-07-10	Entrada Therapeutics, Inc.	Verbindungen und verfahren zum überspringen von exon 44 bei duchenne-muskeldystrophie
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
JP2024535888A (ja)	2021-09-20	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	インヒビンサブユニットベータｅ（ｉｎｈｂｅ）モジュレーター組成物およびその使用方法
KR20240067943A (ko)	2021-09-24	2024-05-17	알닐람 파마슈티칼스 인코포레이티드	미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
AU2022357561A1 (en)	2021-10-01	2024-04-18	Adarx Pharmaceuticals, Inc.	Prekallikrein-modulating compositions and methods of use thereof
US20240401045A1 (en)	2021-10-01	2024-12-05	Adarx Pharmaceuticals, Inc.	Angiotensinogen-modulating compositions and methods of use thereof
EP4416284A1 (de)	2021-10-15	2024-08-21	Alnylam Pharmaceuticals, Inc.	Extrahepatische irna-zusammensetzungen zur abgabe und verfahren zur verwendung davon
AU2022370009A1 (en)	2021-10-22	2024-05-16	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
AR127477A1 (es)	2021-10-29	2024-01-31	Alnylam Pharmaceuticals Inc	COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS
EP4423272A2 (de)	2021-10-29	2024-09-04	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
AU2022391744A1 (en)	2021-11-18	2024-06-27	Cornell University	Microrna-dependent mrna switches for tissue-specific mrna-based therapies
WO2023099884A1 (en)	2021-12-01	2023-06-08	Mina Therapeutics Limited	Pax6 sarna compositions and methods of use
EP4452327A1 (de)	2021-12-20	2024-10-30	Synthorx, Inc.	Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und pembrolizumab
EP4453196A1 (de)	2021-12-21	2024-10-30	Alia Therapeutics Srl	Typ-ii-cas-proteine und anwendungen davon
EP4453191A1 (de)	2021-12-23	2024-10-30	Bayer Aktiengesellschaft	Neuartige programmierbare endonukleasesysteme für kleine v-rna
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
EP4469575A2 (de)	2022-01-24	2024-12-04	Alnylam Pharmaceuticals, Inc.	Enzym-irna-wirkstoffzusammensetzungen für den heparinsulfatbiosyntheseweg und verfahren zur verwendung davon
WO2023166425A1 (en)	2022-03-01	2023-09-07	Crispr Therapeutics Ag	Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023170435A1 (en)	2022-03-07	2023-09-14	Mina Therapeutics Limited	Il10 sarna compositions and methods of use
EP4490187A4 (de)	2022-03-08	2026-02-25	Immunedge Inc	Epo-rezeptor-agonisten und -antagonisten
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
EP4522742A2 (de)	2022-05-13	2025-03-19	Alnylam Pharmaceuticals, Inc.	Einzelsträngige schleifenoligonukleotide
WO2023237587A1 (en)	2022-06-10	2023-12-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
EP4547683A2 (de)	2022-06-30	2025-05-07	Alnylam Pharmaceuticals, Inc.	Oligonukleotid-prodrugs auf basis von mit cyclischem disulfid modifiziertem phosphat
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
CN119907856A (zh)	2022-09-15	2025-04-29	阿尔尼拉姆医药品有限公司	第13型17β-羟基类固醇脱氢酶(HSD17B13)iRNA组合物及其使用方法
EP4587564A2 (de)	2022-09-16	2025-07-23	Alia Therapeutics Srl	Enqp-typ-ii-cas-proteine und anwendungen davon
JP2025532127A (ja)	2022-09-23	2025-09-29	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｍｅｃｐ２発現を低減する化合物及び方法
JP2025532985A (ja)	2022-09-30	2025-10-03	アルナイラムファーマシューティカルズ，インコーポレイテッド	修飾二本鎖ｒｎａ剤
WO2024105162A1 (en)	2022-11-16	2024-05-23	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
US20260209732A1 (en)	2022-12-13	2026-07-23	Bayer Aktiengesellschaft	Engineered type v rna programmable endonucleases and their uses
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
US20260218178A1 (en)	2022-12-22	2026-07-30	Mina Therapeutics Limited	Chemically Modified saRNA Compositions and Methods of Use
JP2026502531A (ja)	2023-01-11	2026-01-23	アリアセラピューティクスエスアールエル	Ｉｉ型ｃａｓタンパク質およびその適用
IL322261A (en)	2023-02-09	2025-09-01	Alnylam Pharmaceuticals Inc	Reverser molecules and methods of using them
WO2024170778A1 (en)	2023-02-17	2024-08-22	Anjarium Biosciences Ag	Methods of making dna molecules and compositions and uses thereof
CN121263208A (zh)	2023-03-20	2026-01-02	新索思股份有限公司	使用il-2 peg缀合物的癌症疗法
KR20260021596A (ko)	2023-04-05	2026-02-13	아이오니스 파마수티컬즈, 인코포레이티드	Pln 발현을 감소시키는 화합물 및 방법
JP2026514045A (ja)	2023-04-12	2026-05-01	アルナイラムファーマシューティカルズ，インコーポレイテッド	二本鎖ｒｎａ剤の肝外デリバリー
EP4698652A2 (de)	2023-04-20	2026-02-25	Adarx Pharmaceuticals, Inc.	Mapt-modulierende zusammensetzungen und verfahren zur verwendung davon
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
WO2024226499A1 (en)	2023-04-24	2024-10-31	The Broad Institute, Inc.	Compositions and methods for modifying fertility
WO2024238385A2 (en)	2023-05-12	2024-11-21	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides
WO2024238396A1 (en)	2023-05-12	2024-11-21	Adarx Pharmaceuticals, Inc.	Nmda ligand conjugated compounds and uses thereof
WO2024249328A2 (en)	2023-05-26	2024-12-05	Adarx Pharmaceuticals, Inc.	Sod1-modulating compositions and methods of use thereof
CN121712891A (zh)	2023-06-20	2026-03-20	阿达尔克斯制药有限公司	Lrrk2调节组合物及其使用方法
WO2025003344A1 (en)	2023-06-28	2025-01-02	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
EP4743577A1 (de)	2023-07-13	2026-05-20	Korro Bio, Inc.	Rna-editierende oligonukleotide und verwendungen davon
KR20260044219A (ko)	2023-07-21	2026-04-01	매로우 테라퓨틱스, 인크.	조혈 세포 표적화 접합체 및 관련 방법
EP4754255A1 (de)	2023-08-04	2026-06-10	Alnylam Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur behandlung von ctnnb1-assoziierten erkrankungen
WO2025059511A1 (en)	2023-09-15	2025-03-20	Praxis Precision Medicines, Inc.	Elsunersen / prax-222 for use in the treatment of scn2a-related disorders
WO2025064660A2 (en)	2023-09-21	2025-03-27	Alnylam Pharmaceuticals, Inc.	Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
AU2024348221A1 (en)	2023-09-27	2026-04-30	Judo Bio Inc.	Aminoglycosides for delivery of agents to the kidney
EP4784172A1 (de)	2023-09-27	2026-08-05	Judo Bio Inc.	Polymyxine zur verabreichung von wirkstoffen an die niere
EP4784753A2 (de)	2023-09-27	2026-08-05	Judo Bio Inc.	Auf slc6a19 abzielende modulatorische nukleinsäurewirkstoffe
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
TW202521691A (zh)	2023-10-06	2025-06-01	美商藍岩醫療公司	經工程化之v型rna可程式核酸內切酶及其用途
WO2025096809A1 (en)	2023-10-31	2025-05-08	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
US20250263702A1 (en)	2024-02-19	2025-08-21	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
WO2025199231A2 (en)	2024-03-20	2025-09-25	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
TW202603156A (zh)	2024-03-25	2026-01-16	美商欣爍克斯公司	用於生產多肽之合成tRNA合成酶及包含合成分子的細胞
WO2025210147A1 (en)	2024-04-04	2025-10-09	Alia Therapeutics Srl	Type v cas proteins and applications thereof
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
TW202615058A (zh)	2024-06-12	2026-04-16	美商艾拉倫製藥股份有限公司	失養強直性肌肉蛋白質激酶（ｄｍｐｋ）ｉｒｎａ組成物及其使用方法
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026027887A2 (en)	2024-08-02	2026-02-05	Mina Therapeutics Limited	Hbg1/2-sarna compositions and methods of use
WO2026050243A1 (en)	2024-08-26	2026-03-05	Korro Bio, Inc.	Galnac conjugated oligonucleotides for rna editing
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
WO2026117631A2 (en)	2024-11-26	2026-06-04	City Therapeutics, Inc.	Factor xi rnai agent compositions and methods of use thereof
WO2026122478A1 (en)	2024-12-02	2026-06-11	Korro Bio, Inc.	Extrahepatic delivery formulations and methods
WO2026136379A1 (en)	2024-12-17	2026-06-25	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4470954A (en) *	1983-06-13	1984-09-11	Chiknas Steven G	Rotor or carrier for centrifugal analyzer and bead washer
DD238395A1 (de) *	1985-06-19	1986-08-20	Akad Wissenschaften Ddr	Verfahren zur selektiven fixierung von biologisch aktiven stoffen
US4806546A (en) *	1985-09-30	1989-02-21	Miles Inc.	Immobilization of nucleic acids on derivatized nylon supports
JPS62197425A (ja) *	1986-02-25	1987-09-01	Toyo Soda Mfg Co Ltd	球状熱可塑性樹脂の製造方法
GB2197720A (en) *	1986-11-20	1988-05-25	Nat Res Dev	Immobilisation of polynucleotides
WO1988006189A1 (en) *	1987-02-12	1988-08-25	Sdi Diagnostics, Inc.	Test system, test device and method for detecting pathogenic organisms and antibiotic resistance genes in body fluids
IL85551A0 (en) *	1987-04-01	1988-08-31	Miles Inc	Rapid hybridization assay and reagent system used therein
US4921805A (en) *	1987-07-29	1990-05-01	Life Technologies, Inc.	Nucleic acid capture method
US4921788A (en) *	1988-04-12	1990-05-01	The Research Foundation Of State University Of New York	Competitive nucleic acid immunoassay for the detection of analytes
IE904365A1 (en) *	1990-02-13	1991-08-14	Epitope	Stick probe device for detection of antibodies

1990
- 1990-09-04 EP EP90309671A patent/EP0455905B1/de not_active Expired - Lifetime
- 1990-09-04 ES ES90309671T patent/ES2116977T3/es not_active Expired - Lifetime
- 1990-09-04 DE DE69032425T patent/DE69032425T2/de not_active Expired - Lifetime
- 1990-09-04 DK DK90309671T patent/DK0455905T3/da active
- 1990-09-04 EP EP96113623A patent/EP0745689A3/de not_active Withdrawn
- 1990-09-04 AT AT90309671T patent/ATE167523T1/de not_active IP Right Cessation
- 1990-09-17 JP JP2244155A patent/JPH0420300A/ja active Pending
1994
- 1994-10-28 US US08/331,296 patent/US5514785A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH0420300A (ja)	1992-01-23
EP0745689A3 (de)	1996-12-11
EP0455905B1 (de)	1998-06-17
DE69032425T2 (de)	1998-11-26
EP0455905A3 (en)	1992-10-07
DK0455905T3 (da)	1998-12-07
EP0455905A2 (de)	1991-11-13
EP0745689A2 (de)	1996-12-04
DE69032425D1 (de)	1998-07-23
US5514785A (en)	1996-05-07
ES2116977T3 (es)	1998-08-01

Legal Events

Date	Code	Title	Description
1999-04-15	UEP	Publication of translation of european patent specification
2007-06-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69032425D1 (de)	1998-07-23	Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden
ATE180570T1 (de)	1999-06-15	Verfahren und vorrichtung zur herstellung von mikromatrizen für biologische proben
ATE279427T1 (de)	2004-10-15	Verfahren zur immobilisierung von nukleinsäure- molekülen
ATE147860T1 (de)	1997-02-15	Verfahren zur immobilisierung von nukleinsäure an einer festen oberfläche zur anwendung in nukleinsäure-hybridizierungstests
ATE220341T1 (de)	2002-07-15	Verfahren zur trennung doppelsträngiger dna von einzelsträngiger dna oder rna
DE69404657D1 (de)	1997-09-04	Verfahren und vorrichtung zur durchfürung einer vielzahl von chemischen reaktionen auf einer traegerflaeche
DE69230736D1 (de)	2000-04-06	Verfahren zur Charakterisierung genomischer DNA
DE69706187D1 (de)	2001-09-20	Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern
DE69535240D1 (de)	2006-11-09	Zusammensetzungen und Verfahren für die gleichzeitige Detektion und Quantifizierung von einer Mehrheit spezifischer Nuklein Säure Sequenzen
ATE91708T1 (de)	1993-08-15	Verfahren zur freisetzung von rns und dns aus zellen.
ATE138197T1 (de)	1996-06-15	Analyseelement und verfahren zu seiner herstellung
DE69840748D1 (de)	2009-05-28	Verfahren zur zubereitung von antisense oligonukleotiden
DE59800705D1 (de)	2001-06-13	Vorrichtung zum automatischen durchführen von chemischen bzw. biologischen verfahren
DE69206080D1 (de)	1995-12-21	Element und verfahren für nuklein-säure amplifikation und nachweis unter verwendung von adhärierten sonden.
WO2002056021A3 (en)	2003-09-18	Polymer brushes for immobilizing molecules to a surface
DE3786388D1 (de)	1993-08-05	Analytisches geraet und verfahren zum nachweis von chlamydia trachomatis und neisseria gonorrhoeae.
ATE334224T1 (de)	2006-08-15	Nukleinsäure-sonden für chlamydia pneumoniae
DE69026024D1 (de)	1996-04-25	Künstlicher Träger zur Immobilisierung von biologischen Proteinen und Verfahren zu seiner Herstellung
DE69029113D1 (de)	1996-12-19	Verfahren zur Bestimmung von Allelen für zystische Fibrose
DE59307931D1 (de)	1998-02-12	Spezifische Gensonden und Verfahren zur Diagnostik von Candida albicans
DE69328951D1 (de)	2000-08-10	Nukleinsäuresonden für Mykobacterium Tuberkulosis
DE59308492D1 (de)	1998-06-10	Fotochemische Markierung von Nukleinsäuren mit Digoxigenin-Reagenzien und ihre Verwendung in Gensondentestsystemen
DE69008690D1 (de)	1994-06-09	Verfahren und Vorrichtung zur Bestimmung von aeroben Bakterien.
DE3675905D1 (de)	1991-01-10	Verfahren zur biologischen denitrifizierung von wasser und vorrichtung zur durchfuehrung dieses verfahrens.
ATE58712T1 (de)	1990-12-15	Verfahren zur biologischen denitrifizierung von wasser und vorrichtung zur durchfuehrung dieses verfahrens.